

Body weight and the gain in each group are shown in Table 1. In the 500 mg/kg group, body weight was significantly reduced on day 7 and from day 21 to the end of the dosing period in males. In females, significant reduction of body weight was found on day 20 of gestation at 150 mg/kg and on days 14 and 20 of gestation at 500 mg/kg. Body weight gain during the whole period of administration in males and during the gestation period in females was significantly decreased in the 150 and 500 mg/kg groups.

Food consumption was significantly decreased on day 21 of the administration period at 50 mg/kg, on day 7 of the administration period at 150 mg/kg and on days 0, 7 and 21 of the administration period at 500 mg/kg in males, and on days 14 and 20 of the gestation period at 150 mg/kg and on day 0 of the pre-mating period and days 0, 14 and 20 of the gestation period at 500 mg/kg in females (data not shown).

At necropsy, the incidence of small-sized thymus, testes and epididymides was significantly increased at 500 mg/kg in males. Significant increase in the incidence of a rough surface and white spots in the spleen was also found in both sexes of the 500 mg/kg group (data not shown).

Absolute and relative organ weight of scheduled-sacrifice animals in each group is shown in Table 2. Absolute pituitary weight was significantly decreased at 150 mg/kg and above in both sexes. Absolute and relative weight of the thymus, testes and epididymides were also significantly decreased in males of the 500 mg/kg group. In addition, significant decreases in absolute kidney weight at 500 mg/kg in males, and increases in the relative kidney weight at 150 mg/kg in females were detected.

On histopathology, test substance-related changes were observed in the thymus, spleen, testes and epididymides, as shown in Table 3. In the thymus, the incidence of atrophy was significantly increased at 500 mg/kg in males. In the spleen, the incidence of capsule inflammation was significantly increased at 500 mg/kg in both sexes, and the grade of extramedullary hematopoiesis was significantly decreased at 150 mg/kg and above in females. Significant increases in the incidence of seminiferous tubular atrophy and hyperplasia of interstitial cells in the testes, and cell debris and decreased sperm in the lumen of epididymides were also detected in males of the 500 mg/kg group.

3.2. Reproductive findings

The reproductive findings in rats given THFA are presented in Table 4. An estrous cycle of over 5 days was observed in only one female each in the control, 150 and 500 mg/kg groups, but the mean estrous cycle at 500 mg/kg was significantly prolonged. One pair at 15 mg/kg did not copulate and the male was found dead on day 7 of the mating period. One female each at 15 and 150 mg/kg did not become impregnated. The copulation index, pre-coital interval and fertility index were not significantly different between the control and THFA-treated groups. All pregnant females at 500 mg/kg and two of 11 pregnant females at 150 mg/kg did not deliver any pups. In these females, total early resorption (1/2 females at 150 mg/kg and 12/12 females at 500 mg/kg) or mummification of all fetuses (1/2 females at 150 mg/kg) were found in the uterus. In the 150 mg/kg group, the

Table 2
Organ weight of male and female rats given tetrahydrofurfuryl alcohol (THFA) by gavage

	Dose (mg/kg/day)				
	0	15	50	150	500
No. of males	12	11	12	12	12
Body weight (g)	550 ± 40	535 ± 30	538 ± 28	517 ± 22	489 ± 33**
Pituitary (mg)	15.6 ± 1.5 (2.8 ± 0.3)	15.6 ± 2.0 (2.9 ± 0.4)	14.2 ± 1.3 (2.7 ± 0.3)	13.4 ± 1.5* (2.6 ± 0.3)	12.2 ± 1.2** (2.5 ± 0.2)
Kidneys (g)	3.10 ± 0.18 (0.57 ± 0.04)	3.15 ± 0.32 (0.59 ± 0.07)	3.09 ± 0.20 (0.58 ± 0.05)	2.90 ± 0.20 (0.56 ± 0.03)	2.71 ± 0.20** (0.55 ± 0.03)
Thymus (g)	0.36 ± 0.07 (0.07 ± 0.01)	0.32 ± 0.06 (0.06 ± 0.01)	0.35 ± 0.06 (0.07 ± 0.01)	0.31 ± 0.07 (0.06 ± 0.01)	0.19 ± 0.05** (0.04 ± 0.01**)
Testes (g)	3.41 ± 0.50 (0.63 ± 0.11)	3.18 ± 0.83 (0.60 ± 0.15)	3.52 ± 0.29 (0.66 ± 0.07)	3.40 ± 0.45 (0.66 ± 0.10)	1.77 ± 0.44** (0.36 ± 0.09**)
Epididymides (g)	1.40 ± 0.20 (0.26 ± 0.04)	1.30 ± 0.30 (0.24 ± 0.05)	1.38 ± 0.15 (0.26 ± 0.03)	1.26 ± 0.17 (0.24 ± 0.04)	0.87 ± 0.15** (0.18 ± 0.03**)
No. of females	12	10	12	9	0
Body weight (g)	363 ± 25	350 ± 35	339 ± 24	313 ± 27**	
Pituitary (mg)	20.1 ± 3.8 (5.5 ± 0.8)	18.3 ± 1.7 (5.3 ± 0.3)	17.6 ± 1.8 (5.2 ± 0.5)	16.0 ± 1.9* (5.1 ± 0.2)	
Kidneys (g)	2.06 ± 0.19 (0.57 ± 0.04)	2.00 ± 0.22 (0.57 ± 0.06)	2.06 ± 0.23 (0.61 ± 0.05)	1.98 ± 0.25 (0.63 ± 0.05*)	
Thymus (g)	0.30 ± 0.08 (0.08 ± 0.02)	0.28 ± 0.09 (0.08 ± 0.03)	0.26 ± 0.07 (0.08 ± 0.02)	0.22 ± 0.05 (0.07 ± 0.01)	

Values are given as the mean ± S.D. Values in parentheses are relative organ weights (g or mg/100 g body weight).

* Significantly different from the control group ($P < 0.05$).

** Significantly different from the control group ($P < 0.01$).

Table 4
Reproductive findings in rats given tetrahydrofurfuryl alcohol (THFA) by gavage

	Dose (mg/kg/day)				
	0	15	50	150	500
No. of pairs	12	12	12	12	12
Estrous cycles (day) ^a	4.3 ± 0.6	4.0 ± 0.1	4.1 ± 0.3	4.5 ± 0.6	4.8 ± 0.5*
Copulation index (male/female) ^b	100/100	91.7/91.7	100/100	100/100	100/100
No. of pairs with successful copulation	12	11	12	12	12
Precoital interval (day) ^a	2.7 ± 1.2	2.5 ± 1.4	2.9 ± 1.2	2.3 ± 1.4	3.7 ± 2.7
Fertility index ^c	100	90.9	100	91.7	100
No. of pregnant females	12	10	12	11	12
No. of pregnant females with parturition	12	10	12	9	0
Gestation length (day) ^a	22.6 ± 0.5	22.7 ± 0.5	22.9 ± 0.3	24.7 ± 0.7**	
Gestation index ^d	100	100	100	36.4**	0**
No. of dams delivering live pups	12	10	12	4	0

^a Values are given as the mean ± S.D.

^b Copulation index (%) = no. of copulated rats/no. of pairs × 100.

^c Fertility index (%) = no. of pregnant females/no. of pairs with successful copulation × 100.

^d Gestation index (%) = no. of dams with live pups/no. of pregnant females × 100.

* Significantly different from the control group ($P < 0.05$).

** Significantly different from the control group ($P < 0.01$).

expected, changes in locomotor activity, lowered body weight, and/or histopathological changes in the thymus, spleen, testes and epididymides were observed at 150 mg/kg and above.

Death at 15 mg/kg was considered to be incidental because death occurred in only one male and showed no dose dependency. Also, the decrease in food consumption found in males of the 50 mg/kg group was considered to be toxicologically insignificant because the decrease was transient and was not accompanied with changes in body weight.

In males, body weight gain during the whole administration period was suppressed at 150 and 500 mg/kg, but decreased food consumption was found only during the early administration period at 500 mg/kg and was transient at 150 mg/kg; therefore, factors other than reduced food consumption must be involved in the inhibitive effect of THFA on body weight. In females, the inhibition of body weight gain during the late gestation period at 150 mg/kg and above is considered to be mainly due to the lack of embryos/fetuses because the total number of pups born was markedly decreased in these groups. Similarly, decreased food consumption during the late gestation period is due to decreased nutritional requirement accompanied with embryonic/fetal loss.

Atrophy of the thymus detected at 500 mg/kg in males was accompanied with a marked decrease in organ weight (about 50% of the control value). In addition to these findings, capsule inflammation and/or decreased extramedullary hematopoiesis detected in the spleen of males at 500 mg/kg and of females at 150 mg/kg and above suggests that THFA affects hematological and immunological parameters. Actually, decreased levels of hemoglobin and/or platelet counts were reported in an unpublished 90-day inhalation and feeding study of THFA using rats [1].

Seminiferous tubular atrophy in the testes could be recognized as direct action on the germinal epithelium or secondary change through decreased secretion of gonadotrophic hormone from the pituitary [17]. In the present study, seminiferous tubular atrophy was associated with hyperplasia of interstitial cells,

which develops with increased levels of luteinizing hormone (LH) in rats [17]; therefore, THFA is considered to exert effects directly on the testes and to impair spermatogenesis. THFA might impair testosterone synthesis, leading to increased LH levels via negative feedback. The reduced pituitary weight found in males in the 150 and 500 mg/kg groups might be related to such disruption of the hypothalamus–pituitary–gonadal axis.

Despite such histopathological changes in the testes with decreased sperm number in the epididymides, no effects of THFA on reproductive parameters, such as precoital interval, copulation and fertility index, were observed in the present study. These findings are supported by the following descriptions by Parker [18]. Rodent males produce sperm in numbers that greatly exceed the minimum requirements for fertility, particularly as evaluated in reproductive studies that allow multiple mating. It is also reported that sperm production can be drastically reduced (by up to 90% more) without affecting fertility in Sprague–Dawley and Wistar rats [19,20].

The prolonged estrous cycle at 500 mg/kg and decreased pituitary weight at 150 mg/kg in females might also suggest disruption of the hypothalamus–pituitary–gonadal axis; however, because the degree of change in the estrous cycle was slight and most females showed 4- to 5-day estrous cycles, this change is considered to be toxicologically insignificant. Parker [18] noted that estrous cyclicity can be impaired at doses below those that alter fertility, and such changes without associated changes in reproductive or hormonal endpoints would not be considered adverse.

In the current study, total embryonic loss was noted in pregnant females in the higher dose groups. These findings were consistent with the previous developmental toxicity study, in which total embryonic loss was found at 500 mg/kg and above [11]. At 150 mg/kg in the present study, most females showed parturition behavior, but only about half of the dams had pups the next day and the total number of pups born markedly decreased. Cannibalism might have occurred in this group. Even animals

Table 5
Developmental findings in rats given tetrahydrofurfuryl alcohol (THFA) by gavage

	Dose (mg/kg/day)				
	0	15	50	150	500
No. of pregnant females	12	10	12	11	12
No. of corpora lutea ^a	17.7 ± 2.1	16.5 ± 2.7	17.8 ± 1.5	16.4 ± 2.0	17.0 ± 2.8
Implantation index ^{a,b}	88.8 ± 7.4	93.5 ± 7.4	90.7 ± 8.0	84.5 ± 13.1	87.9 ± 23.7
No. of implantation sites ^a	15.6 ± 1.3	15.3 ± 1.9	16.1 ± 1.8	13.7 ± 2.1	14.5 ± 3.7
No. of litters	12	10	12	4	0
Delivery index ^{a,c}	95.3 ± 7.1	94.7 ± 6.2	91.9 ± 5.9	46.4 ± 14.0 ^e	
Total no. of pups born ^a	14.8 ± 1.6	14.5 ± 2.1	14.8 ± 1.7	7.0 ± 1.4 ^{**}	
Live birth index ^{a,d}	100 ± 0	100 ± 0	98.8 ± 2.8	43.1 ± 29.3 ^e	
No. of live pups on PND 0 ^a	14.8 ± 1.6	14.5 ± 2.1	14.6 ± 1.8	3.0 ± 2.2 ^{**}	
No. of dead pups on PND 0 ^a	0	0	0.2 ± 0.4	4.0 ± 2.2 ^{**}	
Sex ratio of live pups (male/female)	86/92	72/73	82/93	6/6	
Viability index on PND 4 ^{a,c}	98.9 ± 2.6	99.3 ± 2.1	97.7 ± 3.5	26.7 ± 46.2	
No. of live pups on PND 4 ^a	14.7 ± 1.6	14.4 ± 2.1	14.3 ± 2.0	1.3 ± 2.3 ^{**}	
Body weight of live pups on PND 0 (g) ^a					
Male	7.3 ± 0.7	7.4 ± 0.5	7.1 ± 0.6	5.9 ± 0.6	
Female	7.0 ± 0.6	7.0 ± 0.5	6.9 ± 0.6	6.3 ± 0.1	
Body weight of live pups on PND 4 (g) ^a					
Male	11.8 ± 1.0	11.5 ± 0.7	11.0 ± 1.1	9.1	
Female	11.2 ± 1.0	10.9 ± 0.7	10.7 ± 0.9	8.4	
External examination of pups					
No. of pups (litters) examined	178 (12)	145 (10)	176 (12)	28 (4)	
No. of pups (litters) with malformations	0 (0)	0 (0)	0 (0)	1 (1)	
General edema	0 (0)	0 (0)	0 (0)	1 (1)	
Internal examination of pups					
No. of pups (litters) examined	178 (12)	144 (10)	175 (12)	27 (4)	
No. of pups (litters) with malformations	0 (0)	0 (0)	0 (0)	0 (0)	
No. of pups (litters) with variations	8 (6)	3 (2)	18 (7)	1 (1)	
Thymic remnants in the neck	6 (4)	3 (2)	14 (5)	1 (1)	
Left umbilical artery	2 (2)	0 (0)	4 (4)	0 (0)	

^a Values are given as the mean ± S.D.

^b Implantation index (%) = no. of implantation sites/no. of corpora lutea × 100.

^c Delivery index (%) = total no. of pups born/no. of implantation sites × 100.

^d Live birth index (%) = no. of live pups on PND 0/total no. of pups born × 100.

^e Viability index on PND 4 (%) = no. of live pups on PND 4/no. of live pups on PND 0 × 100.

^{*} Significantly different from the control group ($P < 0.05$).

^{**} Significantly different from the control group ($P < 0.01$).

not ordinarily carnivorous, including nonhuman primates, are nevertheless likely to eat dead and moribund offspring, as well as those with malformations that involve skin lesions allowing the loss of body fluids or the exposure of viscera [21].

The malformations and variations found in the current study are those that occur spontaneously among control rats [22–24], and the incidence in the THFA-treated group was very low and not different from that of the control group. However, in the present study, only external and internal examination was performed for pups, and no skeletal examinations were performed. Furthermore, the effects of THFA on the morphological development of offspring could not be evaluated at higher doses because a sufficient number of offspring was not obtained. To accurately evaluate prenatal developmental toxicity, including teratogenicity, it is necessary to interrupt pregnancy a few hours or days before the expected term, either by hysterectomy or the necropsy of maternal animals [21,25]. Such a prenatal developmental toxicity study of THFA is only available as a dose range-finding study using a small number of animals [11]. In this study, an

insufficient number of fetuses were morphologically examined due to high embryonic loss at 500 mg/kg and above. This prenatal study adopted a wide dose range, and the next lowest dose was 100 mg/kg. Prenatal developmental effects of THFA at the higher dose should be examined with a sufficient number of dams and fetuses.

The present study was performed in compliance with the OECD guideline 421 "Reproduction/Developmental Toxicity Screening Test" [13]. This screening test guideline does not provide complete information on all aspects of reproduction and development due to the relatively small numbers of animals in the dose groups and selectivity of endpoints, and, therefore, had reduced power in detecting any small effects. Although the results of the current study clearly showed the adverse effects of THFA on the reproduction and development of rats, information on the effects of THFA on reproduction and development is not sufficient at this time. The present results showed that a full reproductive and developmental toxicity study of THFA is required.

In conclusion, the results of this reproductive and developmental toxicity study provide a more comprehensive toxicity profile of THFA than has been previously reported, and the NOAELs for parental and reproductive/developmental toxicity were concluded to be 50 mg/kg/day.

Acknowledgement

This study was supported by the Ministry of Health, Labour and Welfare, Japan.

References

- [1] OECD (Organisation for Economic Co-operation and Development). 2-Furanmethanol, tetrahydro-. SIDS documents for SIAM 20, April 19–21, 2005. Available at: <http://cs3-hq.oecd.org/scripts/hpv/>, accessed on August 8, 2007.
- [2] METI (Ministry of Economy, Trade and Industry, Japan). Research results on the actual production and import volume of chemicals in 2004 (in Japanese). Available at: http://www.meti.go.jp/policy/chemical_management/kasinhou/jittaichousa/kakuhouchi18.pdf, accessed on August 8, 2007.
- [3] Penn Specialty Chemicals, Inc. Technical Bulletin of Tetrahydrofurfuryl alcohol. 2005. Available at: <http://www.pschem.com/pdfs/thfbulletin4.pdf>, accessed on August 8, 2007.
- [4] Allen LVJr. Compounding topical dosage forms: ointments, creams, pastes and lotions. *Secundum Artem—current & practical compounding information for the pharmacist*, Vol. 3, No. 2. Minnesota: Paddock Laboratories, Inc. Available at: http://www.paddocklabs.com/forms/secundum/volume_3_2.pdf, accessed on July 30, 2007.
- [5] MHLW (Ministry of Health, Labour and Welfare, Japan). Flavoring agents as food additives. 2003. Available at: <http://www.jetro.go.jp/jpn/regulations/guidebook/pdf/free/flower2003aug-e.pdf#search=Tetrahydrofurfuryl%20alcohol%209799-4>, accessed on July 30, 2007.
- [6] FDA (Food and Drug Administration, USA). Synthetic flavoring substances and adjuvants. Code of Federal Regulations. Title 21, Vol.3, 21 CFR 172.515, lastly amended at 69 FR 24511, May 4, 2004.
- [7] EC (European Commission). Commission decision of 23 February 1999 adopting a register of flavouring substances used in or on foodstuffs drawn up in application of Regulation (EC) No. 2232/96 of the European Parliament and of the Council of 28 October 1996 (1999/217/EC). *Official Journal of the European Communities*. L 84:March 27:1999.
- [8] Deichmann WB, Heyroth FW, Rowe VK, et al. Tetrahydrofurfuryl alcohol. C₄H₇OCH₂OH. In: Fasset DW, Irish DD, editors. *Industrial hygiene and toxicology*, Vol. 2. Sydney: Interscience Publishers; 1963. p. 1491–2.
- [9] Coquet PH, Durand G, Laillier J, Plazonnet B. Evaluation of ocular irritation in the rabbit: objective versus subjective assessment. *Toxicol Appl Pharmacol* 1977;39:129–39.
- [10] Lashmar UT, Hadgraft J, Thomas N. Topical application of penetration enhancers to the skin of nude mice: a histopathological study. *J Pharm Pharmacol* 1989;41:118–22.
- [11] TSCA. A dose range-finding developmental toxicity study in rats with THFA. 8EHQ-1092-8576S; October 1992.
- [12] MHLW (Ministry of Health, Labour, Welfare, Japan). Tetrahydrofurfuryl alcohol. Toxicity testing reports of environmental chemicals, Vol. 11. Tokyo: Chemicals Investigation Promoting Council; 2004. p. 155–194.
- [13] OECD (Organisation for Economic Co-operation and Development). Guideline 421. Reproduction/Developmental Toxicity Screening Test (adopted on July 27, 1995). OECD Guidelines for the Testing of Chemicals, section 5.
- [14] EPA (Environmental Protection Agency, USA). Hazard assessment for the tolerance reassessment of tetrahydrofurfuryl alcohol (THFA). Office of Prevention, Pesticides and Toxic Substances; February, 21; 2006.
- [15] OECD (Organization for Economic Co-operation and Development). Principles on Good Laboratory Practice (revised in 1997). OECD Series on Principles of Good Laboratory Practice and Compliance Monitoring. No. 1.
- [16] EA, MHW, MITI (Environment Agency, Ministry of Health and Welfare, Ministry of International Trade and Industry, Japan). Testing Facility Provided in the Article 4 in the Ordinance Prescribing Test Relating to New Chemical Substances and Toxicity Research of Designated Chemical Substances. Joint notification by Planning and Coordination Bureau, Environment Agency (Kanpogyo No. 39), Pharmaceutical Affairs Bureau, Ministry of Health and Welfare (Yakuhatsu No. 229) and Basic Industries Bureaus, Ministry of International Trade and Industry (Kikyoku No. 85). March 31, 1984, lastly amended on January 23–24, 2001.
- [17] Kandori H, Chatani F, Miyajima H. Male reproductive organs. In: *The Japanese society of toxicologic pathology editor Toxicologic Histopathology* (in Japanese). Tokyo: International Press Editing Centre Incorporation; 2000. p. 283–314.
- [18] Parker RM. Testing for reproductive toxicity. In: Hood RD, editor. *Developmental and reproductive toxicology—a practical approach*. Florida: CRC Press. Taylor & Francis Group; 2006. p. 425–87.
- [19] Robaire B, Smith S, Hales BF. Suppression of spermatogenesis by testosterone in adult male rats: effect on fertility, pregnancy outcome and progeny. *Biol Reprod* 1984;31:221–30.
- [20] Aafjes JH, Vels JM, Schenck E. Fertility of rats with artificial oligozoospermia. *J Reprod Fertil* 1980;58:345–51.
- [21] Wilson JG. Methods for administering agents and detecting malformations in experimental animals. In: Wilson JG, Warkany J, editors. *Teratology: principles and techniques*. Chicago: The University of Chicago Press; 1965. p. 262–77.
- [22] Kameyama Y, Tanimura T, Yasuda M, editors. Spontaneous malformations in laboratory animals-photographic atlas and reference data. *Cong Anom* 1980;20:25–106.
- [23] Morita H, Ariyuki F, Inomata N, Nishimura K, Hasegawa Y, Miyamoto M, et al. Spontaneous malformations in laboratory animals: frequency of external, internal and skeletal malformations in rats, rabbits and mice. *Cong Anom* 1987;27:147–206.
- [24] Nakatsuka T, Horimoto M, Ito M, Matsubara Y, Akaike M, Ariyuki F. Japan Pharmaceutical Manufacturers Association (JPMA) survey on background control data of developmental and reproductive toxicity studies in rats, rabbits and mice. *Cong Anom* 1997;37:47–138.
- [25] Wilson JG. Collection and interpretation of results. In: Wilson JG, editor. *Environment and birth defects*, vol. 1. New York: Academic Press; 1973. p. 173–93.



Potential adverse effects of phthalic acid esters on human health: A review of recent studies on reproduction

Mariko Matsumoto, Mutsuko Hirata-Koizumi, Makoto Ema *

*Division of Risk Assessment, Biological Safety Research Center, National Institute of Health Sciences,
1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan*

Received 10 July 2007

Available online 21 September 2007

Abstract

Various phthalic acid esters (PAEs) have been used for a wide range of products. PAEs and their metabolites produce reproductive and developmental toxicities in laboratory animals. These findings have raised concern about the possibility of PAEs as contributors to reproductive and developmental adverse effects in humans. This paper focuses on PAE exposure and health effects in human populations and summarizes recent studies. The exposure data in human populations indicate that the current methodology of estimation of PAE exposure is inconsistent. It is therefore important to obtain improved data on human PAE exposure and better understanding of the toxicokinetics of PAEs in each subpopulation. Studies on health effects of PAEs in humans have remained controversial due to limitations of the study designs. Some of findings in human populations are consistent with animal data suggesting that PAEs and their metabolites produce toxic effects in the reproductive system. However, it is not yet possible to conclude whether phthalate exposure is harmful for human-reproduction. Studies in human populations reviewed in this paper are useful for showing the strength of the association. It is sometimes claimed that the use of animal data for estimating human risk does not provide strong scientific support. However, because it is difficult to find alternative methods to examine the direct toxic effects of chemicals, animal studies remain necessary for risk assessment of chemicals including PAEs.

© 2007 Elsevier Inc. All rights reserved.

Keywords: Phthalic acid ester; Human health; Reproduction; Development

1. Introduction

Various phthalic acid esters (PAEs) have been used for a wide range of products, and the largest use of these esters is in plasticizers for polyvinyl chloride (PVC) products (Autian, 1973). When used as plasticizers, PAEs are not irreversibly bound to the polymer matrix; therefore, they can migrate from the plastic to the external environment under certain conditions. PAEs are ubiquitous environmental pollutants because of their widespread manufacture, use, and disposal as well as their high concentration in and ability to migrate from plastics (Marx, 1972; Mayer et al., 1972). Humans are exposed to PAEs from food con-

taminated during growth, processing, and packaging or from storage and indoor air. Di-(2-ethylhexyl) phthalate (DEHP), di-*n*-butyl phthalate (DBP), and butyl benzyl phthalate (BBP) were particularly found in fatty foods including dairy products (Kavlock et al., 2002a,b,c). Women have been exposed to DEHP, DBP, and diethyl phthalate (DEP) in cosmetics on a daily basis (Koo and Lee, 2004).

Some PAEs and their metabolites produce reproductive and developmental toxicities in laboratory animals. The major toxicities are known to be testicular effects (Zhang et al., 2004), embryoletality (Ema et al., 1994, 1997a; Tyl et al., 1988), malformations such as cleft palate and fusion of the sternebrae, and adverse effects on sexual differentiation (Ema et al., 1997b, 1998; Gray et al., 2000). There are considerable homologies among different

* Corresponding author. Fax: +81 3 3700 1408.

E-mail address: ema@nihs.go.jp (M. Ema).

mammalian species for androgen activities during sex differentiation (Gray et al., 1994). Chemicals that adversely affect human sex differentiation (Schardein, 2000) also produce predictable alterations of this process in rodents (Gray et al., 1994). The anti-androgenic effects of some PAEs were observed in a Hershberger assay in castrated male rats (Stroheker et al., 2005; Lee and Koo, 2007) or in an AR reporter gene assay (Satoh et al., 2004). These findings have raised concern about the possibility of PAEs as contributors to reproductive and developmental adverse effects in humans. Available data on primates are currently limited but show significant differences from rodents regarding the reproductive effects of PAEs (Kurata et al., 1998; Pugh et al., 2000; Tomonari et al., 2006), indicating the possibility of species-related differences.

The lower sensitivity of primates is thought to arise from differences between rodents and primates in the absorption, distribution, metabolism, and excretion (ADME) of PAEs. Monoester metabolites of PAEs such as mono-2-ethylhexyl phthalate (MEHP) and mono-butyl phthalate (MBP) have been reported to be the active metabolites responsible for adverse effects (Elcombe and Mitchell, 1986; Ema and Miyawaki, 2001; Tomita et al., 1986). DEHP is hydrolyzed to MEHP by the catalytic action of lipase (Ito et al., 2005). Lipase activities in the liver, small intestine, and kidneys are higher in rodents than in primates (Ito et al., 2005). The maximum concentrations of MEHP in the blood of marmosets were up to 7.5 times lower than in rats (Kessler et al., 2004). In rats, MEHP is oxidized to other secondary metabolites, and both MEHP and secondary metabolites are found in the blood and amniotic fluid primarily in their free form (Kurata et al., 2005; Calafat et al., 2006). Urinary MEHP was mostly found as a glucuronide conjugate in rats (Calafat et al., 2006). On the other hand, in humans and primates, MEHP is present in blood and urine primarily as glucuronide conjugates, which enhance urinary excretion and reduce the biological activity of the active metabolites (Ito et al., 2005; Kurata et al., 2005; Silva et al., 2003), but DEHP metabolites with a carboxylated ester side-chain were found as both conjugates and free forms in human urine (Silva et al., 2006a). Plasma radioactivity measurements of DEHP in rats and marmosets revealed that radioactivity in rat testis was about 20-fold higher than that in marmosets. About 60% of the dose was excreted in urine in rats primarily as unconjugated MEHP-metabolites. For marmosets, the majority of the dose was excreted in the feces (Kurata et al., 1998).

The potential of PAEs to produce adverse effects in humans has been the subject of considerable discussion. Many toxicity studies have been conducted in laboratory animals, especially in rats, and review papers are available based on these animal data (Corton and Lapinskas, 2005; Ema, 2002; Foster, 2006); however, studies in human populations have not been adequate to assess the toxic potential on human health. Lately, several review papers were published regarding PAE exposure in human populations (Koch et al., 2006; Latini, 2005; Schettler, 2006). These

review studies are worthwhile for knowing exposure levels and routes of PAE exposure in human populations; however, review works regarding the relationships between PAE exposure and human health are not adequate. In the late 20th century, only a few papers have reported a relationship between environmental PAE exposures and human health (Aldyreva et al., 1975; Fredricsson et al., 1993; Murature et al., 1987). Studies in human populations have been receiving much attention for the last 2 or 3 years, and the number of studies in human populations has increased. Some recent studies have suggested possible associations between environmental exposure to PAEs and adverse effects on human reproductive health. It will be useful to review them to determine whether there is concordance between animal models and human populations in order to develop hypotheses for future studies. This paper focuses on the PAE exposure and health effects in human populations and summarizes recent human studies published up to 2006.

2. Exposure to PAEs

Many studies have suggested that PAEs and their metabolites produce reproductive and developmental toxicities in laboratory animals. Although the most of these animals were exposed to PAEs at relatively high level to exam toxicological effects, some studies showed that relatively low doses of PAEs caused toxic effects (Arcadi et al., 1998; Lee et al., 2004; Poon et al., 1997). Thus, there is a question of whether humans are exposed to PAEs at a severe enough level to generate human health effects. Several studies have been conducted to estimate the exposure level of PAEs in humans.

2.1. Estimate of PAE exposure in human populations

Levels of human exposure to PAEs were estimated from the urinary metabolite of PAEs. Table 1 shows the urinary PAE metabolite in US populations. A pilot study was conducted for measurement of levels of seven urinary phthalate metabolites, MEHP, MBP, mono-benzyl phthalate

Table 1
Total urinary phthalate monoester concentrations (in $\mu\text{g/g}$ of creatinine)

Metabolites	Diester	Measurement in 289 individuals (Blount et al., 2000)		Measurement in 2541 individuals (Silva et al., 2004a)	
		Geometric mean	95th percentile	Geometric mean	95th percentile
MEP	DEP	345	2610	163	1950
MBP	DBP/BBP	36.9	162	22.4	97.5
MBzP	BBP	20.2	91.9	14.0	77.4
McHP	DcHP	0.3	1.0	<LOD	3.00
MEHP	DEHP	3.0	15.2	3.12	18.5
MOP	DOP	0.5	2.1	<LOD	3.51
MINP	DINP	1.3	6.8	<LOD	4.29

LOD, limit of detection.

(MBzP), mono-cyclohexyl phthalate (McHP), mono-ethyl phthalate (MEP), mono-isononyl phthalate (MINP) and mono-*n*-octyl phthalate (MOP), in 289 US adults (Blount et al., 2000). A subsequent study involving a group of 2541 individuals from participants of the National Health and Nutrition Examination Survey (NHANES) aged ≥ 6 years in US provided similar findings to the previous study although urinary levels for MEP, MBP and MBzP were lower than the previously reported values (Silva et al., 2004a).

These urinary metabolite levels were used to calculate the ambient exposure levels for five PAEs, BBP, DBP, DEHP, di-*n*-octyl phthalate (DOP) and di-isononyl phthalate (DINP), in human populations (David et al., 2001; Kohn et al., 2000). The estimation of daily intake of phthalates was calculated by applying the following equation according to David et al. (2001):

$$\text{Intake } (\mu\text{g/kg/day}) = \frac{\text{UE } (\mu\text{g/g}) \times \text{CE } (\text{mg/kg/day})}{f \times 1000 \text{ (mg/g)}} \times \frac{\text{MW}_d}{\text{MW}_m}$$

where UE is the urinary concentration of monoester per gram creatinine, CE is the creatinine excretion rate normalized by body weight, *f* is the ratio of urinary excretion to total elimination, and MW_d and MW_m are the molecular weights of the diesters and monoesters, respectively.

Table 2 shows the estimated ambient exposure to PAEs. As shown in Table 2, all estimated PAE intakes in the US population were lower than the tolerable daily intake (TDI) values settled by the EU Scientific Committee for Toxicity, Ecotoxicity and the Environment (BBP: 200 $\mu\text{g/kg/day}$, DBP: 100 $\mu\text{g/kg/day}$, DEHP: 37 $\mu\text{g/kg/day}$, DOP: 370 $\mu\text{g/kg/day}$, and DINP: 150 $\mu\text{g/kg/day}$) (CSTEE, 1998), the reference dose (RfD) of the US EPA (BBP: 200 $\mu\text{g/kg/day}$, DBP: 100 $\mu\text{g/kg/day}$, and DEHP: 20 $\mu\text{g/kg/day}$) (US EPA, 2006) and the TDI values established by the Japanese Government (DEHP: 40–140 $\mu\text{g/kg/day}$ and DINP: 150 $\mu\text{g/kg/day}$) (MHLW, 2002). Among these PAEs, DEHP is most commonly used plasticizer for flexible PVC formulations and is a widespread environmental contaminant (Kavlock et al., 2002c); however, the

estimated daily intake level of DEHP was not high as expected.

Koch et al. (2004a, 2003) and Barr et al. (2003) cast doubt on the sensitivity of the biomarker MEHP for assessing DEHP exposure, and they explored mono- (2-ethyl-5-oxo-hexyl) phthalate (5oxo-MEHP) and mono- (2-ethyl-5-hydroxyhexyl) phthalate (5OH-MEHP) as additional biomarkers for DEHP. After a single oral dose of DEHP in a male volunteer, peak concentrations of MEHP, 5OH-MEHP, and 5oxo-MEHP were found in the serum after 2 h, and in urine after 2 h (MEHP) and 4 h (5OH-MEHP and 5oxo-MEHP). The major metabolite was MEHP in serum and 5OH-MEHP in urine (Koch et al., 2004a). Barr et al. (2003) analyzed 62 urine samples for metabolites of DEHP, and the mean urinary levels of 5oxo-MEHP and 5OH-MEHP were 4-fold higher than MEHP.

Koch et al. (2003) determined a median DEHP intake of 13.8 $\mu\text{g/kg/day}$ based on urinary oxidative metabolites of DEHP, 5OH-MEHP and 5oxo-MEHP, in male and female Germans ($n = 85$; aged 18–40). Twelve percent of the subjects exceeded the TDI of the EU-CSTEE (37 $\mu\text{g/kg/day}$) and 31% of the subjects exceeded the RfD of the US EPA (20 $\mu\text{g/kg/day}$). For DBP, BBP, DEP, and DOP, the 95th percentile intake values were estimated to be 16.2, 2.5, 22.1, and 0.42 $\mu\text{g/kg/day}$, respectively. Subsequently, urine samples from 254 German children aged 3–14 were also analyzed for concentrations of these three metabolites of DEHP. The geometric means for MEHP, 5OH-MEHP and 5oxo-MEHP in urine were 7.9, 52.1, and 39.9 $\mu\text{g/L}$, respectively (Becker et al., 2004). The median daily intake of DEHP in children was estimated to be 7.7 $\mu\text{g/kg}$. Four children exceeded the TDI of the EU-CSTEE (37 $\mu\text{g/kg/day}$) and 26 children also exceeded the RfD of the US EPA (20 $\mu\text{g/kg/day}$) (Koch et al., 2006).

Although these findings showed that German populations could be exposed to DEHP at a higher level than previously estimated values (David et al., 2001; Kohn et al., 2000), these results should be interpreted carefully. In the above-mentioned equation, Kohn et al. (2000) and David et al. (2001) applied the fractional urinary excretion value ($f = 0.106$: MEHP) determined by Peck and Albro (1982). On the other hand, Koch et al. (2003) applied the fractional urinary excretion values ($f = 0.074$: 5OH-

Table 2
Comparison of calculated intakes of phthalates based on the geometric mean values for urinary metabolites and the tolerable daily intake levels as well as the reference dose of phthalates (in $\mu\text{g/kg/day}$)

PAEs	Estimated by David et al. (2001) for 289 US individuals (Blount et al., 2000)		Estimated by Kohn et al. (2000) for 2541 US individuals (Silva et al., 2004a)		TDI (EU) (CSTEE, 1998)	RfD (US) (US EPA, 2006)	TDI (Japan) (MHLW, 2002)
	Geometric mean	95th percentile	Geometric mean	95th percentile			
BBP	0.73	3.34	0.88	4.0	200	200	Not established
DBP	1.56	6.87	1.5	7.2	100	100	Not established
DEHP	0.60	3.05	0.71	3.6	37	20	40–140
DOP	<LOD	—	0.0096	0.96	370	Not established	Not established
DINP	0.21	1.08	<LOD	1.7	150	Not established	150

LOD, limit of detection.

MEHP, 0.055: 5oxo-MEHP and 0.024: MEHP) determined by Schmid and Schlatter (1985). Using different fractional urinary excretion values can yield several fold differences in estimated values even if the levels of the urinary metabolites are the same.

Table 3 shows a comparison of the estimated median exposure levels of DEHP. Koo and Lee (2005) and Fujimaki et al. (2006) applied the same fractional urinary excretion values of Koch et al. (2003) for calculating daily DEHP intake. Koo and Lee (2005) estimated daily intake of DEHP in Korean children aged 11–12 years old ($n = 150$) and in Korean women aged 20–73 years old ($n = 150$) with a fractional urinary excretion value of 0.024 for MEHP. Median intake levels of DEHP were estimated to be 6.0 $\mu\text{g}/\text{kg}/\text{day}$ in children and 21.4 $\mu\text{g}/\text{kg}/\text{day}$ in adult women. TDI of the EU (37 $\mu\text{g}/\text{kg}/\text{day}$) was reached at the 56th percentile for women and the 95th percentile for children. Fujimaki et al. (2006) estimated the daily intake of DEHP in forty pregnant Japanese women. The median concentrations of MEHP, 5OH-MEHP and 5oxo-MEHP in the urine were 9.83, 10.4, and 10.9 $\mu\text{g}/\text{L}$, respectively. The median DEHP intake based on MEHP, 5OH-MEHP, and 5oxo-MEHP were estimated to be 10.4 (3.45–41.6), 4.55 (0.66–17.9), and 3.51 (1.47–8.57) $\mu\text{g}/\text{kg}/\text{day}$, respectively. These two studies showed higher exposure levels than the previously estimated values in the US population (David et al., 2001; Kohn et al., 2000). Koo and Lee (2005) also showed that a different estimation model can yield 10-fold lower values when estimating DEHP intake, indicating that methods for estimation of daily intake values of PAEs remain inconsistent.

Recently, other secondary oxidized metabolites of DEHP have been recognized (Koch et al., 2005b). Although 5OH-MEHP and 5oxo-MEHP in the urine reflect short-term exposure levels of DEHP, other secondary oxidized metabolites of DEHP such as mono-(2-ethyl-5-carboxypentyl) phthalate (5cx-MEPP) and mono-[2-(carboxymethyl)hexyl] phthalate (2cx-MMHP) are considered excellent parameters for measurement of the time-weighted body burden of DEHP due to their long half-times of elimination. Biological monitoring in a German population ($n = 19$) indicated that 5cx-MEPP is the major urinary

metabolite of DEHP. Median concentrations of the metabolites of DEHP were 85.5 $\mu\text{g}/\text{L}$ (5cx-MEPP), 47.5 $\mu\text{g}/\text{L}$ (5OH-MEHP), 39.7 $\mu\text{g}/\text{L}$ (5oxo-MEHP), 9.8 $\mu\text{g}/\text{L}$ (MEHP) and 36.6 $\mu\text{g}/\text{L}$ (2cx-MMHP) (Preuss et al., 2005). Furthermore, oxidized metabolites of DINP have been recently introduced as new biomarkers for measurement of DINP exposure (Koch and Angerer, 2007; Silva et al., 2006b). These new findings imply that more accurate methods for estimation of PAE exposure can be developed.

2.2. Exposure in fetuses and infants

PAE exposure to the fetus in utero is a great concern because some PAEs are considered to be developmental toxicants. Adibi et al. (2003) measured of urinary phthalate metabolites in pregnant women ($n = 26$) in New York. The median creatinine-adjusted concentrations of MEP, MBP, MBzP, and MEHP were 236, 42.6, 12.1, and 4.06 $\mu\text{g}/\text{g}$, respectively. Metabolites levels in pregnant women were comparable with those in US general population (Blount et al., 2000; Silva et al., 2004a). Another study in 24 mother–infant pairs confirmed DEHP and/or MEHP exposure during human pregnancies (Latini et al., 2003a). The mean DEHP concentrations in maternal plasma and cord plasma were 1.15 and 2.05 $\mu\text{g}/\text{mL}$, respectively, and the mean MEHP concentration was 0.68 $\mu\text{g}/\text{mL}$ in both maternal plasma and cord plasma. The levels of phthalate metabolites in the amniotic fluid may reflect fetal exposure to PAEs. Only three metabolites, MEP, MBP, and/or MEHP, were detected in the amniotic fluid samples ($n = 54$). The levels of mono-methylphthalate (MMP), MBzP, McHP, MINP, MOP, 5OH-MEHP, and 5oxo-MEHP were under the limits of detection. Levels of MEP, MBP, and MEHP ranged from under the limits of detection to 9.0 ng/mL ($n = 13$), 263.9 ng/mL ($n = 50$), and 2.8 ng/mL ($n = 21$), respectively (Silva et al., 2004b). These studies suggest that human exposure to PAEs can begin in utero.

Breast milk and infant formula can be routes of PAE exposure for infants. Table 4 shows phthalate monoesters levels in human milk, infant formula, and consumer milk. Levels of phthalate monoesters in pooled breast milk

Table 3
Comparison of estimated mean daily intake of DEHP ($\mu\text{g}/\text{kg}/\text{day}$)

Metabolites	German ^a adults ($n = 85$) (Koch et al., 2003)	Korean ^a (Koo and Lee, 2005)		Japanese ^a pregnant women ($n = 40$) (Fujimaki et al., 2006)	US ^b adults ($n = 289$) (David et al., 2001)	US ^b aged ≥ 6 years ($n = 2541$) (Kohn et al., 2000)
		Adults (women) ($n = 150$)	Children ($n = 150$)			
MEHP	10.3 (38.3)	21.4 (158.4)	6.0 (37.2)	10.4	0.60 (3.05)	0.71 (3.6)
5OH-MEHP	13.5 (51.4)	No data	No data	4.55	No data	No data
5oxo-MEHP	14.2 (52.8)	No data	No data	3.51	No data	No data
Oxidative DEHP metabolites ^c	13.8 (52.1)	No data	No data	No data	No data	No data

Figures in parentheses show the 95th percentile.

^a Applying the equation of David et al. (2001) and the fractional urinary excretion value determined by Schmid and Schlatter (1985).

^b Applying the equation of David et al. (2001) and the fractional urinary excretion value determined by Peck and Albro (1982).

^c Average of estimated intakes of DEHP based on 5OH-MEHP and 5oxo-MEHP.

Table 4
Phthalate monoester levels ($\mu\text{g/L}$) in human milk, infant formula and consumer milk

Monoester	Diester	Three pooled breast milk samples (Calafat et al., 2004b)	Thirty-six samples of Danish mother's milk (Mortensen et al., 2005)	Ten samples of infant formula (Mortensen et al., 2005)	Seven samples of consumer milk (Mortensen et al., 2005)
MMP	DMP	<LOD	0.17 ± 0.26^a	<LOD	<LOD
MEP	DEP	<LOD	1.78 ± 2.74	<LOD	<LOD
MBP	DBP/ BBP	1.3 ± 1.5^a	359 ± 1830	$0.6\text{--}3.9^b$	$1.4\text{--}2.8^b$
MBzP	BBP	<LOD	1.2 ± 1.6	<LOD	<LOD
MEHP	DEHP	7.8 ± 6.8	13 ± 11	$5.6\text{--}9.1$	$7.1\text{--}9.9$
MINP	DINP	15.9 ± 7.7	114 ± 69	<LOD	<LOD

LOD, limit of detection.

^a Values are given as mean \pm standard deviation.

^b Values are given as range.

($n = 3$) were reported by Calafat et al. (2004b). A subsequent study for 36 individual human milk samples provided higher values for all metabolites; in particular, levels of MBP were two magnitudes higher (Mortensen et al., 2005) than that in the previous study by Calafat et al. (2004b). Phthalate metabolites in breast milk were detected in their free forms unlike the metabolites found in urine and blood. Therefore, infants may receive active PAE metabolites from breast milk on a daily basis. Only MBP and MEHP were detected in consumer milk and infant formula (Mortensen et al., 2005).

The levels of PAEs were determined for 27 infant formulae sold in several countries, and DEHP and DBP were found (Yano et al., 2005). The amounts of DEHP (34–281 ng/g) were much higher than DBP (15–77 ng/g). DEHP, DBP, and DEP were also found in a total of 86 human milk samples collected from 21 Canadian mothers over a 6-month postpartum period. DEHP was the major ester with a mean value of 222 ng/g (8–2920 ng/g), followed by DBP with a mean of 0.87 ng/g (undetectable to 11.39 ng/g). DEP with a mean of 0.31 ng/g (undetectable to 8.1 ng/g) was detected in only a small number of samples. Dimethyl phthalate (DMP), BBP, and DOP were not detected in any samples (Zhu et al., 2006). Table 5 presents estimated maximum daily intakes of PAEs in infants, which was calculated by assuming that the body weight of infants is 7 kg and the daily intake of milk is 700 mL. Although the total estimated maximum daily intake of DEHP in infants was generally less than in general adults (Koch et al., 2003), the estimated maximum daily intake per body weight was higher than adults due to the low

body weight of the infants. Assuming that milk was the only exposure route for PAEs in the infants, it is likely that infants had less exposure to DBP and DEP than the general adult population (Koch et al., 2003). These studies suggest that some infants may also be exposed to DEHP at higher levels than the established safe standard levels.

2.3. Possible variation of PAE exposure

Some humans may be exposed to PAEs at higher level than the established safe standard levels. Measurements of urinary metabolites of PAEs have revealed notable differences in concentrations of specific metabolites based on age, gender and race (Blount et al., 2000; Silva et al., 2004a). Concentrations of MBP, MBzP, and MEHP were higher in the youngest age group (6–11 years) and decreased with age. Non-Hispanic blacks tended to have higher levels of phthalate metabolites than non-Hispanic whites or Mexican Americans. Females tended to have a higher level of phthalate metabolites than did males (Silva et al., 2004a). Blount et al. (2000) also indicated that women of reproductive age (20–40 years) had significantly higher levels of MBP than other age/gender groups. Measurement of the three urinary metabolites MEHP, 5OH-MEHP and 5oxo-MEHP in male and female children ($n = 254$) aged 3 to 14 showed that boys had higher concentrations of these three metabolites of DEHP than girls (Becker et al., 2004). The higher levels of PAE metabolites in the young age group may be due to a different food category, dairy products, or the use of PVC toys (CSTEE, 1998), and the higher levels of MBP in females may be

Table 5
Estimated maximum daily intake ($\mu\text{g/kg/day}$) of PAEs in infants and general German population

Compounds	Human milk ($n = 21$) (Zhu et al., 2006)	Infant formula ($n = 27$) (Yano et al., 2005)	General population ($n = 85$) (Koch et al., 2003)
DEHP	301 (41.1)	6.9	166 (52.1)
DBP	1.21 (0.12)	1.07	22.6 (16.2)
DEP	0.87	Not measured	69.3 (22.1)

Daily PAE intake levels were calculated by assuming that the average daily milk consumption is 700 mL (722 g: specific gravity of human milk = 1.031) and average body weight is 7 kg.

Figures in parentheses show 95th percentile.

due to use of cosmetic products that contain high levels of DBP (Koo and Lee, 2004).

Koo et al. (2002) approached this issue from a different point of view. Their statistical examination concluded that higher levels of MBP in urine were associated with a lower level of education (only a high school education) and/or lower family income (less than \$1500) in the month before sampling. Slightly higher levels of MEP were found in urban populations, low income groups, and males. PAE exposure occurred from food, water, and indoor air, although dietary intake of PAEs from contaminated food was likely to be the largest source (Schettler, 2006). Education level and family income may therefore influence the dietary pattern.

It is still unknown whether the variations in these metabolites represent differences in the actual exposure levels. Metabolism of PAEs may vary by age, race, or sex; for example, the ratios of 5OH-MEHP/5oxo-MEHP and 5oxo-MEHP/MEHP decrease with increasing age (Becker et al., 2004). The mean relative ratios of urinary MEHP to 5OH-MEHP to 5oxo-MEHP were 1 to 7.1 to 4.9 in German male and female children and 1 to 3.4 to 2.1 in German male and female adults. This might indicate enhanced oxidative metabolism in children (Koch et al., 2004b). The ratios for urinary MEHP, 5OH-MEHP and 5oxo-MEHP in Japanese pregnant women were reported to be approximately 1 to 1 to 1 (Fujimaki et al., 2006). The variation seen in these three populations may be due to differences in the analytical methods; however, these variations in human populations are still not negligible for accurate risk assessment. Because the current estimates of PAE intake in humans can be imprecise and ADMEs of PAEs in each subpopulation are not clear, the significance of exposure to PAEs with regard to health effects is yet unknown.

2.4. Exposure from medical devices

DEHP has been used for a wide variety of PVC medical devices such as i.v. storage bags, blood storage bags, tubing sets, and neonatal intensive care units (NICUs), and known treatments that involve high DEHP exposures include blood exchange transfusions, extracorporeal membrane oxygenation and cardiovascular surgery.

Serum concentrations of DEHP were significantly increased in platelet donors and receptors (Buchta et al., 2005, 2003; Koch et al., 2005c). A median increase of 232% of serum DEHP was detected after plateletpheresis in healthy platelet donors (Buchta et al., 2003). Mean DEHP doses for discontinuous-flow platelet donors and continuous-flow platelet donors were 18.1 and 32.3 $\mu\text{g}/\text{kg}/\text{day}$ on the day of apheresis, which were close to or exceeded health standard levels such as the TDI or RfD (Koch et al., 2005c).

Premature infants who experience medical procedures may have a higher risk of exposure to DEHP than the general population. Because the same size of each medical device is used for all ages, infants may receive a larger dose

of PAEs on a mg/kg basis than adults due to their smaller size. Calafat et al. (2004a) provided the first quantitative evidence confirming that infants who undergo intensive therapeutic medical interventions are exposed to higher concentrations of DEHP than the general population. They assessed exposure levels of DEHP in 6 premature newborns (23–26 weeks old) by measuring levels of urinary MEHP, 5OH-MEHP and 5oxo-MEHP. The geometric mean concentrations of MEHP (100 $\mu\text{g}/\text{L}$), 5oxo-MEHP (1617 $\mu\text{g}/\text{L}$), and 5OH-MEHP (2003 $\mu\text{g}/\text{L}$) were found to be one or two orders of magnitude higher than German children aged 3–5 (MEHP: 6.96 $\mu\text{g}/\text{L}$, 5OH-MEHP: 56.7 $\mu\text{g}/\text{L}$ and 5oxo-MEHP: 42.8 $\mu\text{g}/\text{L}$). Koch et al. (2005a) estimated DEHP exposure due to medical devices by using five major DEHP metabolites. Forty-five premature neonates (2–31 days old) with a gestational age of 25–40 weeks at birth were exposed to DEHP up to 100 times over the RfD value set by the US EPA depending on the intensity of medical care (median: 42 $\mu\text{g}/\text{kg}/\text{day}$; 95th percentile: 1780 $\mu\text{g}/\text{kg}/\text{day}$).

3. Health effects of PAEs in human populations

In the late 20th century, a few studies reported a relationship between environmental exposure of PAEs and human health. For example, Murature et al. (1987) reported that there was a negative correlation between DBP concentration in the cellular fraction of ejaculates and sperm production. Fredricsson et al. (1993) reported that human sperm motility was affected by DEHP and DBP. In females, decreased rates of pregnancy and higher levels of miscarriage in factory workers were associated with occupational exposure of DBP (Aldyeva et al., 1975). More recent studies in human males, females and infants are summarized below.

3.1. Studies of the male reproductive system

Table 6 shows a summary of studies of the male reproductive system in human populations. Two studies are available for 168 male subjects who were members of subfertile couples (Duty et al., 2003a,b). Eight urinary PAE metabolites, MEP, mono-methyl phthalate (MMP), MEHP, MBP, MBzP, MOP, MINP and McHP, were measured with a single spot urine sample. Urinary MEHP, MOP, MINP, or McHP showed no relevance to sperm parameters or DNA damage (Duty et al., 2003a,b). Urinary MBP was associated with lower sperm concentration and lower motility, and urinary MBzP was associated with lower sperm concentration. There was limited evidence suggesting an association of increased MMP with poor sperm morphology (Duty et al., 2003a). A neutral comet assay revealed that urinary MEP levels were associated with increased DNA damage in sperm (Duty et al., 2003b). This result was confirmed by a recent study in 379 men from an infertility clinic in which sperm DNA damage was associated with MEP (Hauser et al., 2007).

Table 6
Male reproductive effects in human populations

Compounds	Number of subjects	Related effects	Reference
Total PAEs ^a	n = 21	↓Sperm normal morphology, ↑Percent of single-stranded DNA in sperm	Rozati et al. (2002)
Phthalic acid	n = 234	↑Large testis ^c , ↑Sperm motility ^c	Jonsson et al. (2005)
DEHP	n = 37	↓Semen volume, ↑Rate of sperm malformation	Zhang et al. (2006)
MEHP	n = 187	↓Straight-line velocity and curvilinear velocity of sperm ^d	Duty et al. (2004)
	n = 74	↓Plasma free testosterone	Pan et al. (2006)
%MEHP ^b	n = 379	↑Sperm DNA damage	Hauser et al. (2007)
MEP	n = 168	↑DNA damage in sperm	Duty et al. (2003b)
	n = 234	↑Large testis ^c , ↓Sperm motility, ↓Luteinizing hormone	Jonsson et al. (2005)
	n = 379	↑DNA damage in sperm	Hauser et al. (2007)
	n = 187	↓Sperm linearity ^d , ↑Straight-line velocity and curvilinear velocity of sperm ^{c,d}	Duty et al. (2004)
DBP	n = 37	↓Semen volume	Zhang et al. (2006)
MBP	n = 168	↓Sperm concentration, ↓Sperm motility	Duty et al. (2003a)
	n = 463	↓Sperm concentration, ↓Sperm motility	Hauser et al. (2006)
	n = 187	↓Straight-line velocity and curvilinear velocity of sperm ^d	Duty et al. (2004)
	n = 74	↓Plasma free testosterone	Pan et al. (2006)
	n = 295	↑Inhibin B level ^{c,d}	Duty et al. (2005)
MBzP	n = 168	↓Sperm concentration	Duty et al. (2003a)
	n = 463	↓Sperm concentration ^d	Hauser et al. (2006)
	n = 187	↓Straight-line velocity and curvilinear velocity of sperm ^d	Duty et al. (2004)
	n = 295	↓Follicle-stimulating hormone ^c	Duty et al. (2005)
MMP	n = 168	↑Poor sperm morphology ^d	Duty et al. (2003a)

^a Total level of DMP, DEP, DBP, DEHP and DOP.

^b The urinary concentrations of MEHP divided by sum of MEHP, 5OH-MEHP and 5oxo-MEHP concentrations and multiplied by 100.

^c Data do not support the association of PAEs with reproductive adverse effects in male human populations.

^d Only suggestive association was observed (statistically not significant).

In another study, semen volume, sperm concentration, motility, sperm chromatin integrity and biochemical markers of epididymal and prostatic function were analyzed together with MEP, MEHP, MBzP, MBP, and phthalic acid levels in urine in 234 young Swedish men (Jonsson et al., 2005). Urinary MEP level was associated with fewer motile sperm, more immotile sperm, and lower serum luteinizing hormone (LH) values. However, higher phthalic acid levels were associated with more motile sperm and fewer immotile sperm; therefore, the results for phthalic acid were opposite what had been expected.

A similar study was conducted in 463 male partners of subfertile couples (Hauser et al., 2006). Phthalate metabolites were measured in a single spot urine sample. There were dose–response relationships of MBP with low sperm concentration and motility. There was suggestive evidence of an association between the highest MBzP quartile and low sperm concentration. There were no relationships between MEP, MMP, MEHP or oxidative DEHP metabolites with any of the semen parameters.

Although there were associations between some metabolites of PAEs and sperm count, motility, or morphology, no statistically significant associations between MEP, MBzP, MBP, MEHP, or MMP and sperm progression, sperm vigor, or swimming pattern were observed in 187 subjects. There were only suggestive associations as follows: negative associations between MBzP with straight-line velocity (VSL) or curvilinear velocity (VCL), between MBP with VSL and VCL and between MEHP with VSL and VCL. MEP was positively associated with VSL and VCL but negatively associated with linearity (Duty et al., 2004).

Duty et al. (2005) explored the relationship between urinary phthalate monoester concentrations and serum levels of reproductive hormones in 295 men. In their previous studies (Duty et al., 2003a,b), MBP and MBzP were associated with sperm parameters, and the investigators had hypothesized that inhibin B, a sensitive marker of impaired spermatogenesis (Uher et al., 2003), would be inversely associated with MBP and MBzP. However, MBP exposure was associated with increased inhibin B, although this was of borderline significance. Additionally, MBzP exposure was significantly associated with a decrease in serum follicle-stimulating hormone (FSH) level. The serum FSH level has been used as a marker of spermatogenesis for infertile males in clinical evaluation (Subhan et al., 1995), and it is increased in comparison to normal males (Sina et al., 1975). Therefore, the hormone concentrations did not change in the expected patterns.

DEHP is known to cause adverse effects on the male reproductive system in rodents (Gray et al., 2000), and DNA damage in human lymphocytes is also induced by DEHP and MEHP (Anderson et al., 1999). A Hershberger assay with DEHP or MEHP showed anti-androgenic effects in castrated rats (Stroheker et al., 2005; Lee and Koo, 2007). However, only a few studies have suggested that DEHP could be a reproductive toxicant in humans. Urine and blood samples from 74 male workers at a factory producing unfoamed polyvinyl chloride flooring exposed to DBP and DEHP were compared with samples from 63 unexposed male workers. The exposed workers had significantly elevated concentrations of MBP (644.3 vs. 129.6 µg/g creatinine) and MEHP (565.7 vs. 5.7 µg/g

creatinine) in their urine. The plasma free testosterone level was significantly lower (8.4 vs. 9.7 $\mu\text{g/g}$ creatinine) in the exposed workers than in the unexposed workers. Free testosterone was negatively correlated to MBP and MEHP in the exposed worker group (Pan et al., 2006). Another recent study showed that although the urinary MEHP concentration was not associated with sperm DNA damage, the percentage of DEHP metabolites excreted as MEHP (MEHP%) was associated with increased sperm DNA damage. It is of interest that the oxidative metabolites had inverse relationships with sperm DNA damage (Hausler et al., 2007).

Unlike other studies, the following two studies used diester concentrations for measurement of PAEs. Rozati et al. (2002) reported that the concentration of total PAEs (DMP, DEP, DBP, BBP, DEHP, and DOP) in the seminal plasma was significantly higher in infertile men ($n = 21$) compared to controls ($n = 32$). Correlations were observed between seminal PAEs and sperm normal morphology ($r = -0.769$, $p < .001$), in addition to the % of single-stranded DNA in the sperm ($r = 0.855$, $p < .001$). This study examined only total PAEs, and relationships between individual PAEs and sperm parameters were not identified. Another study in a human male population was carried out by measurement of semen parameters and DEHP, DBP, and DEP in human semen ($n = 37$) (Zhang et al., 2006). The three PAEs were detected in most of the samples, and mean levels of DEHP, DBP, and DEP were 0.28, 0.16, and 0.47 $\mu\text{g/L}$, respectively. There was a negative correlation between semen volume and concentration of DBP or DEHP. There was also a positive association between the rate of sperm malformation and DEHP concentrations. These diester concentrations may directly reflect PAE exposure levels.

Animal data have suggested that mature exposure to DBP and DEHP affects sperm parameters (Agarwal et al., 1986; Higuchi et al., 2003). Dietary exposure of mature male F344 rats (15–16 weeks old) to DEHP (0–20,000 ppm) for 60 consecutive days resulted in a dose dependent reduction in testis, epididymis and prostate weights at 5000 and 20,000 ppm (284.1 and 1156.4 mg/kg/day). Epididymal sperm density and motility were also reduced and there was an increased occurrence of abnormal sperm at 20,000 ppm (Agarwal et al., 1986). Exposure of BBP from adolescence to adulthood showed changes in reproductive hormones in CD(SD)IGS rats at 100 and 500 mg/kg/day (Nagao et al., 2000). In Dutch-Belted rabbits, exposure of DBP during adolescence and in adulthood decreased the amount of normal sperm whereas in utero exposure of DBP decreased the amount of normal sperm, sperm counts, ejaculated volume, and accessory gland weight (Higuchi et al., 2003). Preadolescent male rats appear to have a greater sensitivity to the adverse testicular effects of DEHP than older rats. Akingbemi et al. (2001) demonstrated that preadolescent male rats (21 days old) were more sensitive than young adult animals (62 days old) to 14- or 28-day DEHP exposures that

induced decreases in Leydig cell production of testosterone. PAE effects on male reproductive organs could be influenced by the stage of development, but the data also support the possibility that mature animals are susceptible to PAE exposure. The studies in human populations were in accord with these animal data.

Some studies in human populations have suggested associations between MEP, a metabolite of DEP, and changes in sperm; however, these results regarding to MEP are not supported by animal studies. According to Foster et al. (1980), oral dosing of DEP (1600 mg/kg/day) for 4 days did not damage the testes in young SD rats. In another study, male and female CD-1 mice were given diets with DEP (0–2.5%) for 7 days prior to and during a 98-day cohabitation period. There were no apparent effects on reproductive function in animals exposed to DEP (Lamb et al., 1987).

Furthermore, studies in rodents may have little relevance to humans for the reason that DEHP and DINP do not cause reproductive effects in non-human primates. Pugh et al. (2000) showed no evidence of testicular lesions in young adult cynomolgus monkeys (~2 years old) gavage dosed with 500 mg/kg bw/day DEHP and DINP for 14 days. A study with matured marmosets (12–15 months old) showed that repeated dosing of DEHP at up to 2500 mg/kg bw/day for 13 weeks resulted in no differences in testicular weight, prostate weight, blood testosterone levels, blood estradiol levels or any other aspect of the reproductive system (Kurata et al., 1998). DEHP treatment up to 2500 mg/kg bw/day in marmosets from weaning (3 months old) to sexual maturation (18 months old) produced no evidence of testicular damage. Sperm head counts, zinc levels, glutathione levels and testicular enzyme activities were also not affected (Tomonari et al., 2006). In contrast to data from rabbits and rodents, no testicular effects of DEHP or DINP were found in non-human primates at any ages. The current understanding of how PAEs affects semen parameters, sperm DNA damage, and hormones in human populations is limited and further investigation is required.

3.2. Studies of the female reproductive system

Studies of adult female humans are less numerous than those of adult males. Cobellis et al. (2003) compared plasma concentrations of DEHP and MEHP in endometriotic women ($n = 55$) with control women ($n = 24$), and higher plasma DEHP concentrations were observed in endometriotic women. Similar results were observed in a recent study reported by Reddy et al. (2006). The investigators collected blood samples from 49 infertile women with endometriosis (the study group), 38 infertile women without endometriosis (control group I) and 21 women with proven fertility (control group II). Women with endometriosis showed significantly higher concentrations of DBP, BBP, DOP, and DEHP when compared to both control groups. Upon analysis of cord blood samples of 84 newborns, Latini et al. (2003b) revealed that MEHP-positive

infants had a lower gestational age (38.16 ± 2.34 weeks) than MEHP-negative infants (39.35 ± 1.35 weeks). Intrauterine inflammation due to DEHP and/or MEHP exposure may be a risk factor for prematurity because intrauterine infection/inflammation is a major cause of premature labor. These studies suggest that DEHP may play a role in inducing the intrauterine inflammatory process.

Thelarche, premature breast development, is the growth of mammary tissue in young girls without other manifestations of puberty. Colon et al. (2000) analyzed serum samples from 41 Puerto Rican thelarche patients and 35 age matched controls. Significantly higher levels of DMP, DEP, DBP, DEHP, and MEHP were found in 28 (68%) samples from thelarche patients. This study suggested a possible association between PAEs and premature breast development. However, McKee et al. (2004) stated that the association between PAE exposure and thelarche seems highly unlikely for two reasons. First, the reported exposure levels of PAEs may have reflected contamination since they were very high when compared to recent exposure information. Second, toxicological evidence from the laboratory studies described below do not support any influence on female sexual development.

DEHP exposure at 2000 mg/kg/day for 1–12 days in mature SD rats resulted in decreased serum estradiol levels, prolonged estrous cycles and no ovulation (Davis et al., 1994). A two generation reproductive study in SD rats revealed that oral doses of 500 mg/kg/day BBP caused atrophy of the ovary in one female and significant decreases in absolute and relative ovary weights. However oral doses of up to 500 mg/kg/day BBP did not affect estrous cycles in SD rats (Nagao et al., 2000). Similarly, when DEHP was administered to rats over two generations at up to 9000 ppm (about 900 mg/kg/day) in the diet, there were no effects on the pattern and duration of the estrous cycle in F0 female rats (Schilling et al., 1999). Histological changes in female reproductive organs were also not observed after exposure to di-*n*-propyl phthalate, DBP, di-*n*-pentyl phthalate, DHP, or DEHP (Heindel et al., 1989; Lamb et al., 1987). Although some PAEs have been reported to be weakly estrogenic in estrogen-responsive

human breast cancer cells (Jobling et al., 1995; Sonnenschein et al., 1995; Soto et al., 1995; Zacharewski et al., 1998) and/or in a recombinant yeast screen (Coldham et al., 1997; Harris et al., 1997), no PAEs showed any estrogenic response upon *in vivo* uterotrophic or vaginal cornification assay (Zacharewski et al., 1998). Thus, there is no evidence that PAEs influence the timing of female sexual development in laboratory studies.

3.3. Studies in human infants

Anogenital distance (AGD) is a developmental landmark for the differentiation of the external genitalia and is commonly used as a hormonally sensitive parameter of sex differentiation in rodents. AGD in male rats is normally about twice that in females, and a similar sex difference is observed in humans (Salazar-Martinez et al., 2004). Many studies in male rodents reported a reduction of AGD after prenatal exposure to PAEs (Table 7). Chemicals that adversely affect human sex differentiation (Schardein, 2000) also produce predictable alterations of this process in rodents (Gray et al., 1994). In a Hershberger assay, significant decreases in seminal vesicles, ventral prostate, levator ani/bulbocavernosus muscles weights were observed in animals treated with DEHP, DBP, DINP, di-isodecyl phthalate or MEHP, which suggest that some phthalates possess anti-androgenic activity (Lee and Koo, 2007). Swan et al. (2005) presented the first study of AGD and other genital measurements in relation to PAE exposure in a human population. AGD data were obtained for 134 boys of 2–36 months of age. Mother's urine during pregnancy was assayed for phthalate metabolites. Urinary concentrations of four phthalate metabolites, MEP, MBP, MBzP, and mono-isobutyl phthalate (MiBP), were negatively related to the anogenital index (AGI) which is a weight-normalized index of AGD [AGD/weight (mm/kg)].

In rats, undescended testes were observed in male pups after maternal dosing of BBP, MBzP, DEHP, DBP, or MBP (Table 7). Main et al. (2006) investigated whether phthalate monoesters in human breast milk had any relation to cryptorchidism in newborn boys (1–3 months of

Table 7
Decreased AGD and undescended testes observed in experimental animals

Compounds	Animals	Days of administration	Route	Dose (mg/kg/day)	Decreased male AGD	Undescended testes	Reference
BBP	Wistar rat	GDs 15–17	Gavage	500	+	+	Ema and Miyawaki (2002)
				1000	+	+	
MBzP	Wistar rat	GDs 15–17	Gavage	250	+	+	Ema et al. (2003)
				375	+	+	
DEHP	SD rat	GD 2-PND 21	Gavage	750	+	+	Moore et al. (2001)
				1500	+	+	
DBP	Wistar rat	GDs 11–21	Diet	555	+	+	Ema et al. (1998)
				661	+	+	
DBP	Wistar rat	GDs 15–17	Gavage	500	+	+	Ema et al. (2000)
				1500	+	+	
MBP	Wistar rat	GDs 15–17	Gavage	250	+	+	Ema and Miyawaki (2001)
				500	+	+	

age). The median levels of MMP, MEP, MBP, MBzP, MEHP, and MINP in breast milk were 0.10, 0.95, 9.6, 1.2, 11, and 95 µg/L, respectively. No association was found between phthalate monoester levels and cryptorchidism. However, there were positive correlations for MEP and MBP with sex hormone-binding globulin, MMP, MEP, and MBP with the ratio of LH/free testosterone, and MINP with LH. MBP was negatively correlated with free testosterone. These mother–son cohort studies provided evidence that testicular and genital development may also be vulnerable to perinatal exposure to PAEs.

Although these two studies of human infants indicate possible associations between PAE exposure and the development of the human reproductive system, two follow-up studies of adolescents exposed to DEHP from medical devices as neonates showed no significant adverse effects on their maturity or sexual activity. A comparison of very low birth weight infants who had undergone neonatal intensive care and infants with normal birth weights showed that there were no differences in the rates of sexual intercourse, pregnancy, or live births when the infants became young adults (Hack et al., 2002). Another study indicated that adolescents exposed to DEHP as neonates showed no significant adverse effects on physical growth and pubertal maturity. Thirteen male and 6 female subjects of 14–16 years of age who had undergone extracorporeal membrane oxygenation as neonates had a complete physical examination to evaluate the long-term toxicity of DEHP in infants. Thyroid, liver, renal, and male and female gonadal functions tested were within normal ranges for the given age and sex distribution (Rais-Bahrami et al., 2004).

4. Overall conclusions

In conclusion, exposure data in human populations indicate that the current methodology of estimation of PAEs is inconsistent. It is important to obtain improved data on human PAE exposure and a better understanding of the toxicokinetics of PAEs in each subpopulation. Oxidized metabolites of DEHP and DINP were recently recognized as the major urinary metabolites in humans (Barr et al., 2003; Koch and Angerer, 2007; Koch et al., 2004a, 2005b). These findings could be useful to establish new hypotheses for laboratory studies. Hauser et al. (2007) found that oxidative metabolites of DEHP had a negative association with sperm DNA damage, suggesting that the oxidation of MEHP to 5OH-MEHP and Soxo-MEHP is protective against sperm DNA damage. However, in an *in vitro* study, 5OH-MEHP and Soxo-MEHP, but not DEHP or MEHP, were anti-androgenic (Stroheker et al., 2005). The relevance of this *in vitro* study to findings in human populations is not clear. Therefore, further studies are required to facilitate accurate risk assessments for human health.

Studies of health effects of PAEs in humans have remained controversial due to limitations of the study designs. Some findings in human populations are consis-

tent with animal data suggesting that PAEs and their metabolites produce toxic effects in the reproductive system. However, it is not yet possible to conclude whether phthalate exposure is harmful for human reproduction. Studies in humans have to be interpreted cautiously because they are conducted in a limited number of subjects. Spot samples only reflect recent phthalate exposure due to the short half-life and it has not yet been confirmed whether point estimates are representative of patterns of long exposure, although reproducibility was found for urinary phthalate monoester levels over two consecutive days (Hoppin et al., 2002). The timing of exposure is a critical factor for decreased AGD in animal studies (Ema and Miyawaki, 2001); however, the stage of fetal development was unknown at the time of urine sampling in the study of Swan et al. (2005). Further studies need to be conducted to confirm these results in human populations and identify the potential mechanisms of interaction.

The studies in human populations reviewed in this paper are useful for showing the strength of associations. Evidence from human studies is preferred for risk assessment as long as it is obtained humanely. It is sometimes claimed that the use of animal data for estimating human risk dose not provide strong scientific support. However, because it is difficult to find alternative methods to test the direct toxic effects of chemicals, continuance of studies in animals is required for risk assessment of chemicals including PAEs.

References

- Adibi, J.J., Perera, F.P., Jedrychowski, W., Camann, D.E., Barr, D., Jacek, R., Whyatt, R.M., 2003. Prenatal exposures to phthalates among women in New York City and Krakow, Poland. *Environ. Health Perspect.* 111, 1719–1722.
- Agarwal, D.K., Eustis, S., Lamb IV, J.C., Reel, J.R., Kluwe, W.M., 1986. Effects of di(2-ethylhexyl) phthalate on the gonadal pathophysiology, sperm morphology, and reproductive performance of male rats. *Environ. Health Perspect.* 65, 343–350.
- Akingbemi, B.T., Youker, R.T., Sottas, C.M., Ge, R., Katz, E., Klinefelter, G.R., Zirkin, B.R., Hardy, M.P., 2001. Modulation of rat Leydig cell steroidogenic function by di(2-ethylhexyl)phthalate. *Biol. Reprod.* 65, 1252–1259.
- Aldyreva, M.V., Klimova, T.S., Iziumova, A.S., Timofeevskaja, L.A., 1975. The effect of phthalate plasticizers on the generative function. *Gig. Tr. Prof. Zabol.*, 25–29.
- Anderson, D., Yu, T.W., Hincal, F., 1999. Effect of some phthalate esters in human cells in the comet assay. *Teratog. Carcinog. Mutagen.* 19, 275–280.
- Arcadi, F.A., Costa, C., Imperatore, C., Marchese, A., Rapisarda, A., Salemi, M., Trimarchi, G.R., Costa, G., 1998. Oral toxicity of bis(2-ethylhexyl) phthalate during pregnancy and suckling in the Long-Evans rat. *Food Chem. Toxicol.* 36, 963–970.
- Autian, J., 1973. Toxicity and health threats of phthalate esters: review of the literature. *Environ. Health Perspect.* 4, 3–26.
- Barr, D.B., Silva, M.J., Kato, K., Reidy, J.A., Malek, N.A., Hurtz, D., Sadowski, M., Needham, L.L., Calafat, A.M., 2003. Assessing human exposure to phthalates using monoesters and their oxidized metabolites as biomarkers. *Environ. Health Perspect.* 111, 1148–1151.
- Becker, K., Seiwert, M., Angerer, J., Heger, W., Koch, H.M., Nagorka, R., Rosskamp, E., Schluter, C., Seifert, B., Ullrich, D., 2004. DEHP metabolites in urine of children and DEHP in house dust. *Int. J. Hyg. Environ. Health* 207, 409–417.

- Blount, B.C., Silva, M.J., Caudill, S.P., Needham, L.L., Pirkle, J.L., Sampson, E.J., Lucier, G.W., Jackson, R.J., Brock, J.W., 2000. Levels of seven urinary phthalate metabolites in a human reference population. *Environ. Health Perspect.* 108, 979–982.
- Buchta, C., Bittner, C., Heinzl, H., Hocker, P., Macher, M., Mayerhofer, M., Schmid, R., Seger, C., Dettke, M., 2005. Transfusion-related exposure to the plasticizer di(2-ethylhexyl)phthalate in patients receiving plateletpheresis concentrates. *Transfusion* 45, 798–802.
- Buchta, C., Bittner, C., Hocker, P., Macher, M., Schmid, R., Seger, C., Dettke, M., 2003. Donor exposure to the plasticizer di(2-ethylhexyl)phthalate during plateletpheresis. *Transfusion* 43, 1115–1120.
- Calafat, A.M., Needham, L.L., Silva, M.J., Lambert, G., 2004a. Exposure to di(2-ethylhexyl) phthalate among premature neonates in a neonatal intensive care unit. *Pediatrics* 113, e429–e434.
- Calafat, A.M., Slakman, A.R., Silva, M.J., Herbert, A.R., Needham, L.L., 2004b. Automated solid phase extraction and quantitative analysis of human milk for 13 phthalate metabolites. *J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.* 805, 49–56.
- Calafat, A.M., Brock, J.W., Silva, M.J., Gray Jr., L.E., Reidy, J.A., Barr, D.B., Needham, L.L., 2006. Urinary and amniotic fluid levels of phthalate monoesters in rats after the oral administration of di(2-ethylhexyl) phthalate and di-n-butyl phthalate. *Toxicology* 217, 22–30.
- Cobellis, L., Latini, G., De Felice, C., Razzi, S., Paris, I., Ruggieri, F., Mazzeo, P., Petraglia, F., 2003. High plasma concentrations of di(2-ethylhexyl)-phthalate in women with endometriosis. *Hum. Reprod.* 18, 1512–1515.
- Coldham, N.G., Dave, M., Sivapathasundaram, S., McDonnell, D.P., Connor, C., Sauer, M.J., 1997. Evaluation of a recombinant yeast cell estrogen screening assay. *Environ. Health Perspect.* 105, 734–742.
- Colon, I., Caro, D., Bourdony, C.J., Rosario, O., 2000. Identification of phthalate esters in the serum of young Puerto Rican girls with premature breast development. *Environ. Health Perspect.* 108, 895–900.
- Corton, J.C., Lapinskas, P.J., 2005. Peroxisome proliferator-activated receptors: mediators of phthalate ester-induced effects in the male reproductive tract. *Toxicol. Sci.* 83, 4–17.
- CSTEE, Phthalate migration from soft PVC toys and child-care articles: Opinion expressed at the CSTEE third plenary meeting Brussels, 24 April 1998 (EU Scientific Committee on Toxicity, Ecotoxicity and the Environment) 1998.
- David, R.M., Moore, M.R., Finney, D.C., Guest, D., 2001. Reversibility of the chronic effects of di(2-ethylhexyl)phthalate. *Toxicol. Pathol.* 29, 430–439.
- Davis, B.J., Maronpot, R.R., Heindel, J.J., 1994. Di-(2-ethylhexyl) phthalate suppresses estradiol and ovulation in cycling rats. *Toxicol. Appl. Pharmacol.* 128, 216–223.
- Duty, S.M., Calafat, A.M., Silva, M.J., Brock, J.W., Ryan, L., Chen, Z., Overstreet, J., Hauser, R., 2004. The relationship between environmental exposure to phthalates and computer-aided sperm analysis motion parameters. *J. Androl.* 25, 293–302.
- Duty, S.M., Calafat, A.M., Silva, M.J., Ryan, L., Hauser, R., 2005. Phthalate exposure and reproductive hormones in adult men. *Hum. Reprod.* 20, 604–610.
- Duty, S.M., Silva, M.J., Barr, D.B., Brock, J.W., Ryan, L., Chen, Z., Herrick, R.F., Christiani, D.C., Hauser, R., 2003a. Phthalate exposure and human semen parameters. *Epidemiology* 14, 269–277.
- Duty, S.M., Singh, N.P., Silva, M.J., Barr, D.B., Brock, J.W., Ryan, L., Herrick, R.F., Christiani, D.C., Hauser, R., 2003b. The relationship between environmental exposures to phthalates and DNA damage in human sperm using the neutral comet assay. *Environ. Health Perspect.* 111, 1164–1169.
- Elcombe, C.R., Mitchell, A.M., 1986. Peroxisome proliferation due to di(2-ethylhexyl) phthalate (DEHP): species differences and possible mechanisms. *Environ. Health Perspect.* 70, 211–219.
- Ema, M., 2002. Antiandrogenic effects of dibutyl phthalate and its metabolite, monobutyl phthalate, in rats. *Congenit. Anom. (Kyoto)* 42, 297–308.
- Ema, M., Amano, H., Ogawa, Y., 1994. Characterization of the developmental toxicity of di-n-butyl phthalate in rats. *Toxicology* 86, 163–174.
- Ema, M., Harazono, A., Miyawaki, E., Ogawa, Y., 1997a. Embryolethality following maternal exposure to dibutyl phthalate during early pregnancy in rats. *Bull. Environ. Contam. Toxicol.* 58, 636–643.
- Ema, M., Harazono, A., Miyawaki, E., Ogawa, Y., 1997b. Developmental effects of di-n-butyl phthalate after a single administration in rats. *J. Appl. Toxicol.* 17, 223–229.
- Ema, M., Miyawaki, E., 2001. Adverse effects on development of the reproductive system in male offspring of rats given monobutyl phthalate, a metabolite of dibutyl phthalate, during late pregnancy. *Reprod. Toxicol.* 15, 189–194.
- Ema, M., Miyawaki, E., 2002. Effects on development of the reproductive system in male offspring of rats given butyl phthalate during late pregnancy. *Reprod. Toxicol.* 16, 71–76.
- Ema, M., Miyawaki, E., Hirose, A., Kamata, E., 2003. Decreased anogenital distance and increased incidence of undescended testes in fetuses of rats given monobutyl phthalate, a major metabolite of butyl benzyl phthalate. *Reprod. Toxicol.* 17, 407–412.
- Ema, M., Miyawaki, E., Kawashima, K., 1998. Further evaluation of developmental toxicity of di-n-butyl phthalate following administration during late pregnancy in rats. *Toxicol. Lett.* 98, 87–93.
- Ema, M., Miyawaki, E., Kawashima, K., 2000. Critical period for adverse effects on development of reproductive system in male offspring of rats given di-n-butyl phthalate during late pregnancy. *Toxicol. Lett.* 111, 271–278.
- Foster, P.M., 2006. Disruption of reproductive development in male rat offspring following in utero exposure to phthalate esters. *Int. J. Androl.* 29, 140–147, discussion 181–185.
- Foster, P.M., Thomas, L.V., Cook, M.W., Gangolli, S.D., 1980. Study of the testicular effects and changes in zinc excretion produced by some n-alkyl phthalates in the rat. *Toxicol. Appl. Pharmacol.* 54, 392–398.
- Fredricsson, B., Moller, L., Pousette, A., Westerholm, R., 1993. Human sperm motility is affected by plasticizers and diesel particle extracts. *Pharmacol. Toxicol.* 72, 128–133.
- Fujimaki, K., Yoshinaga, J., Watanabe, C., Serizawa, S., Shiraiishi, H., Mizumoto, Y., 2006. Estimation of intake level of di(2-ethylhexyl) phthalate (DEHP) in Japanese pregnant women based on measurement of concentrations of three urinary metabolites. *Nippon Eiseigaku Zasshi* 61, 340–347.
- Gray Jr., L.E., Ostby, J., Furr, J., Price, M., Veeramachaneni, D.N., Parks, L., 2000. Perinatal exposure to the phthalates DEHP, BBP, and DNP, but not DEP, DMP, or DOTP, alters sexual differentiation of the male rat. *Toxicol. Sci.* 58, 350–365.
- Gray Jr., L.E., Ostby, J.S., Kelce, W.R., 1994. Developmental effects of an environmental antiandrogen: the fungicide vinclozolin alters sex differentiation of the male rat. *Toxicol. Appl. Pharmacol.* 129, 46–52.
- Hack, M., Flannery, D.J., Schluchter, M., Cartar, L., Borawski, E., Klein, N., 2002. Outcomes in young adulthood for very-low-birth-weight infants. *N. Engl. J. Med.* 346, 149–157.
- Harris, C.A., Henttu, P., Parker, M.G., Sumpter, J.P., 1997. The estrogenic activity of phthalate esters in vitro. *Environ. Health Perspect.* 105, 802–811.
- Hauser, R., Meeker, J.D., Duty, S., Silva, M.J., Calafat, A.M., 2006. Altered semen quality in relation to urinary concentrations of phthalate monoester and oxidative metabolites. *Epidemiology* 17, 682–691.
- Hauser, R., Meeker, J.D., Singh, N.P., Silva, M.J., Ryan, L., Duty, S., Calafat, A.M., 2007. DNA damage in human sperm is related to urinary levels of phthalate monoester and oxidative metabolites. *Hum. Reprod.* 22, 688–695.
- Heindel, J.J., Gulati, D.K., Mounce, R.C., Russell, S.R., Lamb IV, J.C., 1989. Reproductive toxicity of three phthalic acid esters in a continuous breeding protocol. *Fundam. Appl. Toxicol.* 12, 508–518.
- Higuchi, T.T., Palmer, J.S., Gray Jr., L.E., Veeramachaneni, D.N., 2003. Effects of dibutyl phthalate in male rabbits following in utero, adolescent, or postpubertal exposure. *Toxicol. Sci.* 72, 301–313.

- Hoppin, J.A., Brock, J.W., Davis, B.J., Baird, D.D., 2002. Reproducibility of urinary phthalate metabolites in first morning urine samples. *Environ. Health Perspect.* 110, 515–518.
- Ito, Y., Yokota, H., Wang, R., Yamanoshita, O., Ichihara, G., Wang, H., Kurata, Y., Takagi, K., Nakajima, T., 2005. Species differences in the metabolism of di(2-ethylhexyl) phthalate (DEHP) in several organs of mice, rats, and marmosets. *Arch. Toxicol.* 79, 147–154.
- Jobling, S., Reynolds, T., White, R., Parker, M.G., Sumpter, J.P., 1995. A variety of environmentally persistent chemicals, including some phthalate plasticizers, are weakly estrogenic. *Environ. Health Perspect.* 103, 582–587.
- Jonsson, B.A., Richthoff, J., Rylander, L., Giwercman, A., Hagmar, L., 2005. Urinary phthalate metabolites and biomarkers of reproductive function in young men. *Epidemiology* 16, 487–493.
- Kavlock, R., Boekelheide, K., Chapin, R., Cunningham, M., Faustman, E., Foster, P., Golub, M., Henderson, R., Hinberg, I., Little, R., Seed, J., Shea, K., Tabacova, S., Tyl, R., Williams, P., Zacharewski, T., 2002a. NTP Center for the Evaluation of Risks to Human Reproduction: phthalates expert panel report on the reproductive and developmental toxicity of butyl benzyl phthalate. *Reprod. Toxicol.* 16, 453–487.
- Kavlock, R., Boekelheide, K., Chapin, R., Cunningham, M., Faustman, E., Foster, P., Golub, M., Henderson, R., Hinberg, I., Little, R., Seed, J., Shea, K., Tabacova, S., Tyl, R., Williams, P., Zacharewski, T., 2002b. NTP Center for the Evaluation of Risks to Human Reproduction: phthalates expert panel report on the reproductive and developmental toxicity of di-n-butyl phthalate. *Reprod. Toxicol.* 16, 489–527.
- Kavlock, R., Boekelheide, K., Chapin, R., Cunningham, M., Faustman, E., Foster, P., Golub, M., Henderson, R., Hinberg, I., Little, R., Seed, J., Shea, K., Tabacova, S., Tyl, R., Williams, P., Zacharewski, T., 2002c. NTP Center for the Evaluation of Risks to Human Reproduction: phthalates expert panel report on the reproductive and developmental toxicity of di(2-ethylhexyl) phthalate. *Reprod. Toxicol.* 16, 529–653.
- Kessler, W., Numtip, W., Grote, K., Csanady, G.A., Chahoud, I., Filser, J.G., 2004. Blood burden of di(2-ethylhexyl) phthalate and its primary metabolite mono(2-ethylhexyl) phthalate in pregnant and nonpregnant rats and marmosets. *Toxicol. Appl. Pharmacol.* 195, 142–153.
- Koch, H.M., Angerer, J., 2007. Di-iso-nonylphthalate (DINP) metabolites in human urine after a single oral dose of deuterium-labelled DINP. *Int. J. Hyg. Environ. Health* 210, 9–19.
- Koch, H.M., Angerer, J., Drexler, H., Eckstein, R., Weisbach, V., 2005a. Di(2-ethylhexyl)phthalate (DEHP) exposure of voluntary plasma and platelet donors. *Int. J. Hyg. Environ. Health* 208, 489–498.
- Koch, H.M., Bolt, H.M., Angerer, J., 2004a. Di(2-ethylhexyl)phthalate (DEHP) metabolites in human urine and serum after a single oral dose of deuterium-labelled DEHP. *Arch. Toxicol.* 78, 123–130.
- Koch, H.M., Bolt, H.M., Preuss, R., Angerer, J., 2005b. New metabolites of di(2-ethylhexyl)phthalate (DEHP) in human urine and serum after single oral doses of deuterium-labelled DEHP. *Arch. Toxicol.* 79, 367–376.
- Koch, H.M., Bolt, H.M., Preuss, R., Eckstein, R., Weisbach, V., Angerer, J., 2005c. Intravenous exposure to di(2-ethylhexyl)phthalate (DEHP): metabolites of DEHP in urine after a voluntary platelet donation. *Arch. Toxicol.* 79, 689–693.
- Koch, H.M., Drexler, H., Angerer, J., 2003. An estimation of the daily intake of di(2-ethylhexyl)phthalate (DEHP) and other phthalates in the general population. *Int. J. Hyg. Environ. Health* 206, 77–83.
- Koch, H.M., Drexler, H., Angerer, J., 2004b. Internal exposure of nursery-school children and their parents and teachers to di(2-ethylhexyl)phthalate (DEHP). *Int. J. Hyg. Environ. Health* 207, 15–22.
- Koch, H.M., Preuss, R., Angerer, J., 2006. Di(2-ethylhexyl)phthalate (DEHP): human metabolism and internal exposure—an update and latest results. *Int. J. Androl.* 29, 155–165, discussion 181–185.
- Kohn, M.C., Parham, F., Masten, S.A., Portier, C.J., Shelby, M.D., Brock, J.W., Needham, L.L., 2000. Human exposure estimates for phthalates. *Environ. Health Perspect.* 108, A440–A442.
- Koo, H.J., Lee, B.M., 2004. Estimated exposure to phthalates in cosmetics and risk assessment. *J. Toxicol. Environ. Health A67*, 1901–1914.
- Koo, H.J., Lee, B.M., 2005. Human monitoring of phthalates and risk assessment. *J. Toxicol. Environ. Health A68*, 1379–1392.
- Koo, J.W., Parham, F., Kohn, M.C., Masten, S.A., Brock, J.W., Needham, L.L., Portier, C.J., 2002. The association between biomarker-based exposure estimates for phthalates and demographic factors in a human reference population. *Environ. Health Perspect.* 110, 405–410.
- Kurata, Y., Kidachi, F., Yokoyama, M., Toyota, N., Tsuchitani, M., Katoh, M., 1998. Subchronic toxicity of Di(2-ethylhexyl)phthalate in common marmosets: lack of hepatic peroxisome proliferation, testicular atrophy, or pancreatic acinar cell hyperplasia. *Toxicol. Sci.* 42, 49–56.
- Kurata, Y., Makinodan, F., Shimamura, N., Okada, M., Katoh, M., 2005. Metabolism of di(2-ethylhexyl) phthalate (DEHP) in juvenile and fetal marmoset and rat. Abstract No. 1251. 2005 Itinerary Planner. New Orleans, LA: Society of Toxicology.
- Lamb, J.C.T., Chapin, R.E., Teague, J., Lawton, A.D., Reel, J.R., 1987. Reproductive effects of four phthalic acid esters in the mouse. *Toxicol. Appl. Pharmacol.* 88, 255–269.
- Latini, G., 2005. Monitoring phthalate exposure in humans. *Clin. Chim. Acta.* 361, 20–29.
- Latini, G., De Felice, C., Presta, G., Del Vecchio, A., Paris, I., Ruggieri, F., Mazzeo, P., 2003a. Exposure to Di(2-ethylhexyl)phthalate in humans during pregnancy. A preliminary report. *Biol. Neonate* 83, 22–24.
- Latini, G., De Felice, C., Presta, G., Del Vecchio, A., Paris, I., Ruggieri, F., Mazzeo, P., 2003b. In utero exposure to di-(2-ethylhexyl)phthalate and duration of human pregnancy. *Environ. Health Perspect.* 111, 1783–1785.
- Lee, B., Koo, H., 2007. Hershberger assay for antiandrogenic effects of phthalates. *J. Toxicol. Environ. Health A70*, 1365–1370.
- Lee, K.Y., Shibutani, M., Takagi, H., Kato, N., Takigami, S., Uneyama, C., Hirose, M., 2004. Diverse developmental toxicity of di-n-butyl phthalate in both sexes of rat offspring after maternal exposure during the period from late gestation through lactation. *Toxicology* 203, 221–238.
- Main, K.M., Mortensen, G.K., Kaleva, M.M., Boisen, K.A., Damgaard, I.N., Chellakooty, M., Schmidt, I.M., Suomi, A.M., Virtanen, H.E., Petersen, D.V., Andersson, A.M., Toppari, J., Skakkebaek, N.E., 2006. Human breast milk contamination with phthalates and alterations of endogenous reproductive hormones in infants three months of age. *Environ. Health Perspect.* 114, 270–276.
- Marx, J.L., 1972. Phthalic acid esters: biological impact uncertain. *Science* 178, 46–47.
- Mayer, F.L., Stalling, D.L., Johnson, J.L., 1972. Phthalate esters as environmental contaminants. *Nature* 238, 411–413.
- McKee, R.H., Butala, J.H., David, R.M., Gans, G., 2004. NTP center for the evaluation of risks to human reproduction reports on phthalates: addressing the data gaps. *Reprod. Toxicol.* 18, 1–22.
- MHLW, Notification of Pharmaceutical and Food Safety Bureau; Yakushoku-hatsu No. 0611001 Amendments to standards for devices, containers package and toys. 2002.
- Moore, R.W., Rudy, T.A., Lin, T.M., Ko, K., Peterson, R.E., 2001. Abnormalities of sexual development in male rats with in utero and lactational exposure to the antiandrogenic plasticizer Di(2-ethylhexyl) phthalate. *Environ. Health Perspect.* 109, 229–237.
- Mortensen, G.K., Main, K.M., Andersson, A.M., Leffers, H., Skakkebaek, N.E., 2005. Determination of phthalate monoesters in human milk, consumer milk, and infant formula by tandem mass spectrometry (LC-MS-MS). *Anal. Bioanal. Chem.* 382, 1084–1092.
- Murature, D.A., Tang, S.Y., Steinhardt, G., Dougherty, R.C., 1987. Phthalate esters and semen quality parameters. *Biomed. Environ. Mass Spectrom.* 14, 473–477.
- Nagao, T., Ohta, R., Marumo, H., Shindo, T., Yoshimura, S., Ono, H., 2000. Effect of butyl benzyl phthalate in Sprague-Dawley rats after gavage administration: a two-generation reproductive study. *Reprod. Toxicol.* 14, 513–532.

- Pan, G., Hanaoka, T., Yoshimura, M., Zhang, S., Wang, P., Tsukino, H., Inoue, K., Nakazawa, H., Tsugane, S., Takahashi, K., 2006. Decreased serum free testosterone in workers exposed to high levels of di-n-butyl phthalate (DBP) and di-2-ethylhexyl phthalate (DEHP): a cross-sectional study in China. *Environ. Health Perspect.* 114, 1643–1648.
- Peck, C.C., Albro, P.W., 1982. Toxic potential of the plasticizer Di(2-ethylhexyl) phthalate in the context of its disposition and metabolism in primates and man. *Environ. Health Perspect.* 45, 11–17.
- Poon, R., Lecavalier, P., Mueller, R., Valli, V.E., Procter, B.G., Chu, I., 1997. Subchronic oral toxicity of di-n-octyl phthalate and di(2-Ethylhexyl) phthalate in the rat. *Food Chem. Toxicol.* 35, 225–239.
- Preuss, R., Koch, H.M., Angerer, J., 2005. Biological monitoring of the five major metabolites of di-(2-ethylhexyl)phthalate (DEHP) in human urine using column-switching liquid chromatography-tandem mass spectrometry. *J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.* 816, 269–280.
- Pugh Jr., G., Isenberg, J.S., Kamendulis, L.M., Ackley, D.C., Clare, L.J., Brown, R., Lington, A.W., Smith, J.H., Klaunig, J.E., 2000. Effects of di-isononyl phthalate, di-2-ethylhexyl phthalate, and clofibrate in cynomolgus monkeys. *Toxicol. Sci.* 56, 181–188.
- Rais-Bahrami, K., Nunez, S., Revenis, M.E., Luban, N.L., Short, B.L., 2004. Follow-up study of adolescents exposed to di(2-ethylhexyl) phthalate (DEHP) as neonates on extracorporeal membrane oxygenation (ECMO) support. *Environ. Health Perspect.* 112, 1339–1340.
- Reddy, B.S., Rozati, R., Reddy, B.V., Raman, N.V., 2006. Association of phthalate esters with endometriosis in Indian women. *BJOG* 113, 515–520.
- Rozati, R., Reddy, P.P., Reddanna, P., Mujtaba, R., 2002. Role of environmental estrogens in the deterioration of male factor fertility. *Fertil. Steril.* 78, 1187–1194.
- Salazar-Martinez, E., Romano-Riquer, P., Yanez-Marquez, E., Longnecker, M.P., Hernandez-Avila, M., 2004. Anogenital distance in human male and female newborns: a descriptive, cross-sectional study. *Environ. Health* 3, 8.
- Satoh, K., Nonaka, R., Ikeda, M., Satoh, T., Kamimura, H., Nagai, F., 2004. Study on androgenic and anti-androgenic effects of phthalate esters with the reporter gene assay using AR-EcoScreen, stable transfected CHO-K1 cells. *Ann. Rep. Tokyo Metr. Inst. PH.* 55, 307–314.
- Schardein, J., 2000. *Hormones and Hormonal Antagonists. Chemically Induced Birth Defects.* Marcel Dekker, New York, pp. 281–357.
- Schettler, T., 2006. Human exposure to phthalates via consumer products. *Int. J. Androl.* 29, 134–139, discussion 181–185.
- Schilling, K., Gembardt, C., Hellwig, J., 1999. Reproduction toxicity of di-2-ethylhexyl phthalate (DEHP). *Toxicol. Sci.* 48 (1-S), 147–148.
- Schmid, P., Schlatter, C., 1985. Excretion and metabolism of di(2-ethylhexyl)phthalate in man. *Xenobiotica* 15, 251–256.
- Silva, M.J., Barr, D.B., Reidy, J.A., Kato, K., Malek, N.A., Hodge, C.C., Hurtz 3rd, D., Calafat, A.M., Needham, L.L., Brock, J.W., 2003. Glucuronidation patterns of common urinary and serum monoester phthalate metabolites. *Arch. Toxicol.* 77, 561–567.
- Silva, M.J., Barr, D.B., Reidy, J.A., Malek, N.A., Hodge, C.C., Caudill, S.P., Brock, J.W., Needham, L.L., Calafat, A.M., 2004a. Urinary levels of seven phthalate metabolites in the U.S. population from the National Health and Nutrition Examination Survey (NHANES) 1999–2000. *Environ. Health Perspect.* 112, 331–338.
- Silva, M.J., Reidy, J.A., Herbert, A.R., Preau Jr., J.L., Needham, L.L., Calafat, A.M., 2004b. Detection of phthalate metabolites in human amniotic fluid. *Bull. Environ. Contam. Toxicol.* 72, 1226–1231.
- Silva, M.J., Reidy, J.A., Preau, J.L., Samandar, E., Needham, L.L., Calafat, A.M., 2006a. Measurement of eight urinary metabolites of di(2-ethylhexyl) phthalate as biomarkers for human exposure assessment. *Biomarkers* 11, 1–13.
- Silva, M.J., Reidy, J.A., Preau Jr., J.L., Needham, L.L., Calafat, A.M., 2006b. Oxidative metabolites of diisononyl phthalate as biomarkers for human exposure assessment. *Environ. Health Perspect.* 114, 1158–1161.
- Sina, D., Schuhmann, R., Abraham, R., Taubert, H.D., Dericks-Tan, J.S., 1975. Increased serum FSH levels correlated with low and high sperm counts in male infertile patients. *Andrologia* 7, 31–37.
- Sonnenschein, C., Soto, A.M., Fernandez, M.F., Olea, N., Olea-Serrano, M.F., Ruiz-Lopez, M.D., 1995. Development of a marker of estrogenic exposure in human serum. *Clin. Chem.* 41, 1888–1895.
- Soto, A.M., Sonnenschein, C., Chung, K.L., Fernandez, M.F., Olea, N., Serrano, F.O., 1995. The E-SCREEN assay as a tool to identify estrogens: an update on estrogenic environmental pollutants. *Environ. Health Perspect.* 103 (Suppl. 7), 113–122.
- Stroheker, T., Cabaton, N., Nourdin, G., Regnier, J.F., Lhuguenot, J.C., Chagnon, M.C., 2005. Evaluation of anti-androgenic activity of di(2-ethylhexyl)phthalate. *Toxicology* 208, 115–121.
- Subhan, F., Tahir, F., Ahmad, R., Khan, Z.D., 1995. Oligospermia and its relation with hormonal profile. *J. Pak. Med. Assoc.* 45, 246–247.
- Swan, S.H., Main, K.M., Liu, F., Stewart, S.L., Kruse, R.L., Calafat, A.M., Mao, C.S., Redmon, J.B., Tennand, C.L., Sullivan, S., Teague, J.L., 2005. Decrease in anogenital distance among male infants with prenatal phthalate exposure. *Environ. Health Perspect.* 113, 1056–1061.
- Tomita, I., Nakamura, Y., Yagi, Y., Tutikawa, K., 1986. Fetotoxic effects of mono-2-ethylhexyl phthalate (MEHP) in mice. *Environ. Health Perspect.* 65, 249–254.
- Tomonari, Y., Kurata, Y., David, R.M., Gans, G., Kawasuso, T., Katoh, M., 2006. Effect of di(2-ethylhexyl) phthalate (DEHP) on genital organs from juvenile common marmosets: I. Morphological and biochemical investigation in 65-week toxicity study. *J. Toxicol. Environ. Health A69*, 1651–1672.
- Tyl, R.W., Price, C.J., Marr, M.C., Kimmel, C.A., 1988. Developmental toxicity evaluation of dietary di(2-ethylhexyl)phthalate in Fischer 344 rats and CD-1 mice. *Fundam. Appl. Toxicol.* 10, 395–412.
- Uhler, M.L., Zinaman, M.J., Brown, C.C., Clegg, E.D., 2003. Relationship between sperm characteristics and hormonal parameters in normal couples. *Fertil. Steril.* 79 (Suppl 3), 1535–1542.
- US EPA, Integrated Risk Information System. 2006. Available from: <<http://www.epa.gov/iris/index.html>>.
- Yano, K., Hirose, N., Sakamoto, Y., Katayama, H., Moriguchi, T., Asaoka, K., 2005. Phthalate levels in baby milk powders sold in several countries. *Bull. Environ. Contam. Toxicol.* 74, 373–379.
- Zacharewski, T.R., Meek, M.D., Clemons, J.H., Wu, Z.F., Fielden, M.R., Matthews, J.B., 1998. Examination of the in vitro and in vivo estrogenic activities of eight commercial phthalate esters. *Toxicol. Sci.* 46, 282–293.
- Zhang, Y., Jiang, X., Chen, B., 2004. Reproductive and developmental toxicity in F1 Sprague-Dawley male rats exposed to di-n-butyl phthalate in utero and during lactation and determination of its NOAEL. *Reprod. Toxicol.* 18, 669–676.
- Zhang, Y.H., Zheng, L.X., Chen, B.H., 2006. Phthalate exposure and human semen quality in Shanghai: a cross-sectional study. *Biomed. Environ. Sci.* 19, 205–209.
- Zhu, J., Phillips, S.P., Feng, Y.L., Yang, X., 2006. Phthalate esters in human milk: concentration variations over a 6-month postpartum time. *Environ. Sci. Technol.* 40, 5276–5281.

有機スズ化合物の生殖発生毒性

江馬 眞

Reproductive and Developmental Toxicity of Organotin Compounds

Makoto Ema

Organotin compounds are chemicals widely used in agriculture and industry. Widespread use of organotins has caused increasing amounts to be released into the environment. Organotins show many aspects of toxicity, such as immunotoxicity, neurotoxicity, and reproductive/developmental toxicity. However, the reproductive and developmental toxicity of organotins is not well understood. The findings of the studies on reproductive and developmental effects of organotin compounds in mammals were summarized in this review.

Keywords: Organotin, reproductive toxicity, developmental toxicity, implantation failure, teratogenicity

1. はじめに

有機スズ化合物は農業や工業の分野で広く使われている^{1, 2)}。四価のスズ化合物は主に他の有機スズ化合物生産の中間体として使用されている。三価の有機スズ化合物は殺生物作用を有しており、防衛剤、ダニ駆虫剤、ネズミ駆散剤、軟体動物駆除剤等として、また、船底防汚剤として広く用いられている。特に、トリフェニルスズ (TPT) とトリブチルスズ (TBT) は藻類駆除剤、軟体動物駆除剤として、防汚剤製品中によく使われてきた。二価の有機スズ化合物は商業上で最も重要な誘導体であり、主にプラスチック工業の分野でポリマーの劣化を防止するためにポリ塩化ビニル (PVC) プラスティックの熱、光安定剤として使われている。一価の有機スズ化合物はPVCの安定剤として使用されている。有機スズ化合物の生産量をTable 1に示した。

近年の有機スズ化合物の広範な使用により有機スズ化合物による環境汚染の懸念が高まっている。農薬としての使用以外の有機スズ化合物の環境汚染の経路は、PVC プラスティックの安定剤として使われた有機スズ化合物の水中への溶出であり³⁾、また、船底防汚剤としての使用が水環境汚染の原因となっている⁴⁾。海棲生物⁵⁻⁷⁾ や海産物⁸⁻¹²⁾ からTBTやTPTが検出されており、カキ¹³⁾、泥ガニ¹⁴⁾、ムールガイ¹⁵⁾、チヌークサーモン¹⁶⁾、イルカ、マグロ及びサメ¹⁷⁾ における食物連鎖によるTBTの生物濃

Table 1. スズ化合物の生産量

物質名	CAS	生産量 (トン)
Dibutyltin dichloride	683-18-1	10,000 - 15,000
Dibutyltin dilaurate	77-58-7	1000 - 5000
Dibutyltin maleate	78-04-6	500 - 1000
Dibutyltin oxide	818-08-6	1000 - 5000
Dibutyltin bis (2-ethylhexylmercap-acetate)	10584-98-2	7,500 - 12,500
Dibutyltin bis (isooctyl mercap-acetate)	25168-24-5	Not available
Dimethyltin dichloride	753-73-1	1,000 - 5,000
Dimethyltin bis (2-ethylhexyl mercap-acetate)	57583-35-4	5,000 - 10,000
Dimethyltin bis (isooctyl mercap-acetate)	26636-01-1	Not available
Diocetyl tin dichloride	3542-36-7	5,000 - 10,000
Diocetyl tin bis (2-ethylhexyl mercap-acetate)	15571-58-1	7,500 - 12,500
Diocetyl tin bis (isooctyl mercap-acetate)	26401-86-5	Not available
Monobutyltin trichloride	1118-46-3	10,000-15,000
Monobutyltin tris (2-ethylhexyl mercap-acetate)	26864-37-9	2,500-7,500
Monobutyltin tris (isooctyl mercap-acetate)	25852-70-4	Not available
Monomethyltin trichloride	993-16-8	1,000 - 5,000
Methyltin Reverse Ester Tallate	201687-57-2	7,500 - 10,000
Monomethyltin tris (2-ethylhexylmercap-acetate)	57583-34-3	5,000 - 10,000
Monomethyltin tris (isooctylmercap-acetate)	54849-38-6	Not available
Mono-octyltin trichloride	3091-25-6	1,000 - 5,000
Mono-octyltin tris (2-ethylhexylmercap-acetate)	27107-89-7	2,500 - 7,500
Mono-octyltin tris (isooctylmercap-acetate)	26401-86-5	Not available
Tributyltin chloride	1461-22-9	2500 - 3000
Tetrabutyltin	1461-25-2	10,000 - 12,500
Tetraoctyltin	3590-84-9	2,500 - 7,500
Tin Tetrachloride	7646-78-8	20,000 - 25,000

出典 : ORTEP Association. 2004. Global production data

To whom correspondence should be addressed:

Makoto Ema; Kamiyoga 1-18-1, Setagaya, Tokyo 158-8501, Japan; Phone: +81-3700-9878; Fax: +81-3-9700-1408; E-mail: ema@nihs.go.jp

縮, またコイ¹⁰⁾及びカプトガニ¹⁸⁾における食物連鎖によるTPTの生物濃縮が報告されている。ヒトは海産物を通じて有機スズを摂取しており, 滋賀県人のTBTの1日摂取量は4.7-6.9 µg (1991年), 2.2-6.7 µg (1992年), TPTの1日摂取量は4.7-6.9 µg (1991年), 2.2-6.7 µg (1992年)であり¹⁹⁾, また, 1998年のトータルダイエット方式調査による日本人の1日摂取量は, TPT: 0.09 µg, ジフェニルスズ (DPT) : 0 µg, TBT: 1.7 µg, ジブチルスズ (DBT) : 0.45 µgと報告されている¹⁹⁾。これらの値はFAO/WHO合同残留農薬専門家会議によるTPTの許容1日摂取量 (25 µg)²⁰⁾及びtributyltin oxide (TBTO) の経口曝露指針値 (18 µg)²¹⁾よりも低く, 海産物中の有機スズ濃度はヒトの健康に悪影響を及ぼすほど高くはない^{11, 19)}と考えられるが, Belfoidら (2000)⁹⁾は, ヒトの健康影響の可能性について結論を下すためには海産物中のTBT含量についての更なる研究が必要であると述べている。

近年, 環境汚染物質による内分泌系の障害の結果, 野生動物の生殖に対する悪影響が惹起される可能性が指摘されている²²⁾。TBT及びTPTは内分泌攪乱作用が疑われる物質とされており²³⁾, 低濃度で巻貝のインポセックス (imposex: 雌にペニスと輸精管が形成される現象), さらに繁殖障害を引き起こす²⁴⁾ことから, 哺乳類における生殖発生毒性が懸念されている。

有機スズ化合物の一般毒性については古くから比較的良好に知られている^{2, 21, 25-28)}が, 生殖発生毒性の理解は十分ではない。本稿では, Ema M and Hirose A (2006)²⁹⁾ Reproductive and developmental toxicity of organotin compounds. In Metals, Fertility, and Reproductive Toxicity, CRC Pressの実験動物における生殖発生毒性の項を基に最近の新たな知見を加えて, 有機スズ化合物の生殖発生毒性について概説した。

2. フェニルスズ化合物の生殖毒性

2-1 トリフェニルスズ (TPT) の生殖毒性

TPTは昆虫の不妊化剤として知られている³⁰⁾。Table 2にTPTの生殖毒性試験の結果を示した。雄に対する影響として, 100または200 ppmのtriphenyltin hydroxide (TPTH) を含む飼料を64日間与えた雄Sharmanラットを無処置雌ラットと繰り返し5回交配させたところ, 体重増加及び摂餌量の著しい低下とともに, 受精率, 出産生児数及び交配あたりの生児数の低下が認められたが, 摂餌量の回復とともに受精率が回復したことが報告されている³¹⁾。Holtzmanラットに20 mg/kgのtriphenyltin acetate (TPTA) またはtriphenyltin chloride (TPTCl) を19日間混餌投与したとき, 体重及び精巣重量への影響が顕著であった。精巣では, 精細管の精上皮細胞層の減少, ステージの進行した精上皮細胞の減少及び精細管腔の狭小

化等の精巣の退行性変化がみられ, TPTAを投与したときにより強い毒性が観察されている³²⁾。同様に, 20 mg/kgのTPTAまたはTPTClのHoltzmanラットへの20日間混餌投与により精子形成が障害されたが, 70日間正常飼料を与えると精子形成の完全な回復がみられた³³⁾。ICR/Ha SwissマウスにTPTA (2.4, 12 mg/kg) またはTPTH (1.3, 8.5 mg/kg) を単回腹腔内投与, もしくはTPTA (6mg/kg) またはTPTH (11 mg/kg) を5日間連続強制経口投与した後に, 無処置雌と交配させ, 妊娠13日に剖検した結果, 優性致死作用は認められなかった³⁴⁾。

TPTの雌動物における生殖毒性についても報告がある。20 mg/kgのTPTAまたはTPTClのHoltzmanラットへの4日間混餌投与により, 成熟卵胞の減少, 初期卵胞の閉鎖の増加, 黄体の著しい減少が観察されている³⁵⁾。このような現象は排卵の減少, 延いては受胎率の低下の原因となる。

ラットの妊娠初期にTPTClを投与したときの妊娠の成立及び維持に対する影響が検討されている³⁶⁾。Wistarラットの妊娠0-3日に3.1, 4.7, 6.3 mg/kgまたは妊娠4-6日に6.3, 12.5, 25.0 mg/kgのTPTClを強制経口投与したところ, 用量依存的な着床阻害が引き起こされ, 妊娠0-3日の4.7 mg/kg以上, 妊娠4-6日の12.5 mg/kg以上で妊娠率の低下が観察された。着床前胚死亡率の増加は妊娠0-3日の4.7 mg/kg以上でみられたが, TPTCl投与群の妊娠が成立した雌における着床数, 生存胎児数, 着床前及び着床後の胚死亡率は対照群と同様であった。これらの結果は妊娠初期に投与したTPTClは着床阻害作用を示し, 着床前に投与した方が強い影響を及ぼすことを示している。

子宮内膜の正常な機能は胚生存のために重要であり, 子宮の脱落膜化は正常な着床及び胎盤形成, その後の正常妊娠の維持に必須である。偽妊娠動物における内膜創傷による子宮内膜の変化は, 胚の着床によって惹起される妊娠子宮における脱落膜反応と同様であり^{37, 38)}, 着床に関連した母体の生理学的変化のモデルとなりうる³⁷⁾。この方法を用いて脱落膜反応を誘起することにより化学物質の生殖発生毒性を母体と胚/胎児とに分けて検討することが可能となる^{37, 41)}。TPTClの着床阻害作用の原因を明らかにするために, 子宮機能に対する作用が偽妊娠Wistarラットを用いて検討されている⁴²⁾。ラットの偽妊娠0-3日にTPTCl (3.1, 4.7, 6.3 mg/kg) を強制経口投与し, 偽妊娠4日の11:00から13:00の間に麻酔下で偽妊娠ラットの子宮内膜を創傷することにより脱落膜反応を誘起し, 偽妊娠9日の子宮重量を子宮脱落膜化の指標として測定した⁴³⁾。その結果, 子宮重量の低下 (子宮脱落膜化の抑制), 偽妊娠4及び9日の血清中プロゲステロン低下が4.7 mg/kg以上の投与でみられた。この投与量は妊娠0-3日に投与したときには着床前胚致死を引き起こす